Therapeutic methods and compositions using adipose tissue-derived stromal vascular cells
Patent Information
- Application Number
- JP2023528631
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-13
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for lung disorders, neurodegenerative disorders, brain injuries, psychiatric disorders, metabolic disorders, and pain are inadequate or cause undesirable side effects, highlighting the need for more effective and safer therapies.
Administering a population of interstitial vascular cells derived from adipose tissue to patients through a specific intravenous administration schedule, using a sonication process without enzymes or sonication probes to obtain the cells, ensuring high purity and viability, and optionally preceded by saline administration to enhance systemic distribution.
The method improves the systemic distribution of stem cells, reducing symptoms of targeted disorders by up to 50% within specified timeframes, providing symptomatic relief or potential cure without adverse side effects.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application Serial No. 63 / 113,481, filed November 13, 2020, the contents of which are incorporated herein by reference in their entirety.
[0002] The present invention provides methods and compositions utilizing adipose tissue-derived stromal vascular cells to treat a variety of medical disorders, including pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain. [Background technology]
[0003] Adipose tissue can be used as a source of multipotent stem cells. See Zuk et al. (2002) Mol Biol Cell. 13:4279-4295. Adipose tissue can be processed to generate stromal vascular cell populations containing multiple cell types, including, for example, pre-adipose tissue, mesenchymal stem cells (MSCs), endothelial progenitor cells, blood endothelial cells, fibroblasts, pericytes, regulatory T cells, and macrophages. See, for example, Koh et al. (2011) Arterioscler Thromb Vasc Biol. 31(5):1141-50. Mesenchymal stem cells (MSCs) can be differentiated into various cell lineages, including adipogenic, chondrogenic, myogenic, and osteogenic lineages. See, e.g., Rodriguez et al. (2012) International Archives of Medicine 5:1-9; Zuk et al. (2001) Tissue Eng. 7:211-228; Hicok et al. (2004) Tissue Eng. 10:371-380; and Erickson et al. (2002) Biochem Biophys Res Commun. 290:763-769. Stromal vascular cells can be administered to a patient to provide a medical benefit.
[0004] Patients suffering from medical disorders such as pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain can benefit from minimally invasive therapies that provide symptomatic relief or even cure of the disorder. Pulmonary disorders such as chronic obstructive pulmonary disorder, asthma, bronchitis, emphysema, and acute respiratory distress syndrome are currently treated inadequately or cause unwanted adverse side effects, affecting a significant number of patients. Similarly, there is an unmet need for more effective and / or safer therapies to treat neurodegenerative disorders, brain injury, and psychiatric disorders. Pain and metabolic disorders such as diabetes mellitus continue to adversely affect the quality of life of many patients, especially elderly patients, and new therapies are needed to treat these diseases.
[0005] Thus, there is a need for improved treatments for pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, pain, and other disorders. The present invention addresses this need and provides other related advantages. Summary of the Invention
[0006] The present invention provides methods and compositions utilizing adipose tissue-derived stromal vascular cells to treat various medical disorders, such as pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain. The methods provide specific treatment protocols useful for administering stromal vascular cells containing a large number of cells to a patient. The treatment protocols describe intravenous administration procedures for administering an injectable pharmaceutical composition containing saline and stromal vascular cells to a patient in need of treatment, often providing for administration of the injectable pharmaceutical composition containing saline and stromal vascular cells to the patient over multiple days separated by specific time periods. Additional features of the method are described, such as the number of cells to be administered to the patient, the rate at which the injectable pharmaceutical composition is administered intravenously to the patient, characteristics of the cells from the stromal vascular cells administered to the patient, and the optional intravenous administration of saline to the patient prior to administration of the injectable pharmaceutical composition containing saline and stromal vascular cells. Prior to initiating intravenous administration of an injectable pharmaceutical composition containing saline and stromal vascular cells on a given day, intravenous administration of saline to a patient improves the systemic distribution of stem cells from the stromal vascular cells in the patient's circulatory system, providing benefits in treating disorders such as neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain. Without prior intravenous administration of saline, stem cells from intravenously administered stromal vascular cells tend to collect in the patient's lungs. Preferably, the stromal vascular cells are obtained by processing adipose tissue obtained from a patient, where the adipose tissue is processed using a sonication procedure that does not use enzymes or sonication probes. The absence of enzymes and sonication probes reduces the risk of contaminating the stromal vascular cells, and purity of the stromal vascular cells is particularly important when the stromal vascular cells are administered to a patient via intravenous injection. These and other features of the methods and compositions are described in more detail below.
[0007] One aspect of the present invention is a method for treating a lung injury, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the lung injury according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0008] Another aspect of the present invention is a method for treating a neurodegenerative disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0009] Another aspect of the present invention is a method for treating a disorder selected from the group consisting of brain injury and psychiatric disorders, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0010] Another aspect of the present invention is a method for treating a metabolic disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0011] Another aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0012] Another aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 120 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0013] Another aspect of the present invention is a method for treating or preventing coronavirus infection in a patient, comprising intravenously administering to a patient in need thereof a population of stromal vascular cells according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0014] The stromal vascular cells used in this method are obtained by processing adipose tissue obtained from a patient, and the adipose tissue is preferably processed using a sonication procedure that does not use enzymes or sonication probes. The cell population in the stromal vascular cells preferably has a cell viability of at least 90%, more preferably at least 95%. One advantage of the methods described herein is that a large population of cells in the stromal vascular cells can be obtained from a patient's adipose tissue and administered to the patient on the same day. For example, adipose tissue can be obtained from a patient and then processed to provide stromal vascular cells, and an aliquot of the stromal vascular cells can then be administered to the patient all on the same day, sometimes within 5, 6, 7, or 8 hours of starting the procedure to isolate adipose tissue from the patient.
[0015] Pharmaceutical compositions and medical kits for use in the methods of treatment are provided. The pharmaceutical compositions are preferably injectable pharmaceutical compositions suitable for intravenous administration to a patient. DETAILED DESCRIPTION OF THE INVENTION
[0016] The present invention provides methods and compositions utilizing adipose tissue-derived stromal vascular cells to treat various medical disorders, such as pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain. The methods provide specific treatment protocols useful for administering stromal vascular cells containing a large number of cells to a patient. The treatment protocols describe intravenous administration procedures for administering an injectable pharmaceutical composition containing saline and stromal vascular cells to a patient in need of treatment, often providing for administration of the injectable pharmaceutical composition containing saline and stromal vascular cells to the patient over multiple days separated by specific time periods. Additional features of the method are described, such as the number of cells to be administered to the patient, the rate at which the injectable pharmaceutical composition is administered intravenously to the patient, characteristics of the cells from the stromal vascular cells administered to the patient, and the optional intravenous administration of saline to the patient prior to administration of the injectable pharmaceutical composition containing saline and stromal vascular cells. Prior to initiating intravenous administration of an injectable pharmaceutical composition containing saline and stromal vascular cells on a given day, intravenous administration of saline to a patient improves the systemic distribution of stem cells from the stromal vascular cells in the patient's circulatory system, providing benefits in treating disorders such as neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain. Without prior intravenous administration of saline, stem cells from intravenously administered stromal vascular cells tend to collect in the patient's lungs. Preferably, the stromal vascular cells are obtained by processing adipose tissue obtained from a patient, where the adipose tissue is processed using a sonication procedure that does not use enzymes or sonication probes. The absence of enzymes and sonication probes reduces the risk of contaminating the stromal vascular cells, and purity of the stromal vascular cells is particularly important when the stromal vascular cells are administered to a patient via intravenous injection. These and other features of the methods and compositions are described in more detail below. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology.Such techniques are explained in such references as "Comprehensive Organic Synthesis" (B.M. Trost & I. Fleming, eds., 1991-1992), "Handbook of Experimental Immunology" (D.M. Weir & C.C. Blackwell, eds.), "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987, and periodic updates), and "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991), each of which is incorporated herein by reference in its entirety.
[0017] Various aspects of the invention are described in the following sections, however, an aspect of the invention described in one particular section should not be limited to any particular section. Further, if a variable is not accompanied by a definition, the variable's previous definition controls.
[0018] definition Terms used in this specification have their ordinary meaning, and the meaning of such terms is independent at each occurrence. Nevertheless, unless otherwise stated, the following definitions apply throughout the specification and claims.
[0019] As used herein, the words "a" and "an" mean "one or more" and include plurals unless the context is inappropriate.
[0020] As used herein, the term "about" refers to within ±10% of the stated value. The invention includes embodiments where a value is within ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the stated value.
[0021] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murine, simian, equine, bovine, porcine, canine, feline, etc.), and most preferably, humans.
[0022] As used herein, the term "effective amount" refers to the amount of a therapeutic agent that produces a beneficial or desired result (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages, and is not intended to be limited to a particular formulation or route of administration. As used herein, the term "treating" includes any effect, e.g., decrease, reduction, modulation, improvement, or elimination, that results in an improvement of a condition, disease, disorder, etc., or an improvement of the symptoms thereof.
[0023] As used herein, the term "pharmaceutical composition" refers to a combination of an active agent with an inert or active carrier, the composition being particularly suitable for in vivo or ex vivo diagnostic or therapeutic use.
[0024] As used herein, the term "pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, such as phosphate-buffered saline solution, water, emulsions (e.g., oil / water or water / oil emulsions), and various types of wetting agents. The composition may also contain stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA
[1975] .
[0025] As used herein, the term "saline" refers to an aqueous solution containing water and sodium chloride. In certain embodiments, saline can be an aqueous solution containing 0.90% w / v NaCl. In certain embodiments, saline can be an aqueous solution containing a sufficient amount of NaCl to provide an osmolality of 308 mOsm / L. Saline is desirably used for intravenous administration to a patient, and saline can be used as a carrier in pharmaceutical compositions for intravenous administration to a patient, such as pharmaceutical compositions containing stem cells. Saline can be isotonic to promote tolerance when administered intravenously to a patient.
[0026] Throughout this specification, when compositions are described as having, including, or comprising certain components, or when processes and methods are described as having, including, or comprising certain steps, it is further contemplated that there are compositions of the invention that consist essentially of, or consist of, the recited components, and that there are processes and methods of the invention that consist essentially of, or consist of, the recited processing steps.
[0027] Generally, compositions specifying percentages are by weight unless otherwise specified.
[0028] I. Therapeutic method using stromal vascular cells The present invention provides methods for treating various disorders by administering stromal vascular cells to a patient. Exemplary disorders for treatment include, for example, pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain, which are described in more detail below.
[0029] A. Methods for Treating Pulmonary Disorders One aspect of the present invention provides methods for treating pulmonary disorders, which are described in more detail below.
[0030] First Method One aspect of the present invention is a method for treating a lung injury, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the lung injury according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0031] Second Method Another aspect of the present invention is a method for treating a pulmonary disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the pulmonary disorder according to the following administration schedule: a. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by b. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; and c. intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; and d. A fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0032] In certain embodiments, step (b) is performed at least one day after step (a). In certain embodiments, step (b) is performed one day after step (a). In certain embodiments, step (c) is performed at least one day after step (b). In certain embodiments, step (c) is performed one day after step (b). In certain embodiments, step (d) is performed at least one day after step (c). In certain embodiments, step (d) is performed one day after step (c).
[0033] In a more specific embodiment, the present invention provides a method for treating a pulmonary disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat the pulmonary disorder: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. Three days after day 1, a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is intravenously administered to a patient in need thereof.
[0034] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0035] In some embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0036] In some embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0037] In some embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0038] In some embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0039] Additional Exemplary Features of the First and Second Methods for Treating a Pulmonary Disorder Additional exemplary features that can characterize the first and second methods for treating a pulmonary disorder described herein are provided below, including, for example, features of the injectable pharmaceutical composition, the pulmonary disorder treated, and the results produced by the method. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0040] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical composition, such as the number of cells in the stromal vascular cell population in the injectable pharmaceutical composition, the volume of saline in the composition, and the total volume of the injectable pharmaceutical composition.
[0041] For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing about 900 million to about 1.5 billion cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing about 400 million to about 1 billion cells. In certain embodiments, a third injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing about 400 million to about 1 billion cells. In certain embodiments, a fourth injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing about 400 million to about 1 billion cells.
[0042] In certain embodiments, the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline.
[0043] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the third injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL.
[0044] Additional Method Steps The method may be further characterized according to the additional steps the method further comprises. For example, in certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide the stromal vascular cells used in the first injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0045] In certain embodiments, this method is characterized in that immediately before the first injectable pharmaceutical composition is intravenously administered, saline is not intravenously administered to the patient.If the first injectable pharmaceutical composition is intravenously administered to the patient at high speed without immediately before the administration of saline, the concentration of stem cells from the interstitial vascular cell population of the patient's lungs will be increased, which will be beneficial when treating lung disorders.
[0046] Lung disorders that should be treated The method may be further characterized according to the pulmonary disorder being treated. For example, in certain embodiments, the pulmonary disorder is chronic obstructive pulmonary disease. In certain embodiments, the pulmonary disorder is asthma. In certain embodiments, the pulmonary disorder is bronchitis. In certain embodiments, the pulmonary disorder is chronic bronchitis. In certain embodiments, the pulmonary disorder is emphysema. In certain embodiments, the pulmonary disorder is acute respiratory distress syndrome. In certain embodiments, the pulmonary disorder is an infection by a coronavirus. In certain embodiments, the pulmonary disorder is an infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In certain embodiments, the coronavirus infection is an infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In certain embodiments, the coronavirus infection is an infection by a mutant strain of SARS-CoV-2. In certain embodiments, the coronavirus infection is an infection by a mutant strain of SARS-CoV-2 that has the spike protein of SARS-CoV-2. In certain embodiments, the coronavirus infection is an infection by SARS-CoV-2 or a variant thereof selected from B.1.617.2, cluster 5, lineage B.1.1.207, lineage B.1.1.7, variant of concern 202102 / 02, lineage B.1.1.317, lineage B.1.1.318, lineage B.1.351, lineage B.1.429, lineage B.1.525, lineage P.1 (also known as lineage B.1.1.28), D614G, E484K, N501Y, S477G / N, and P681H.
[0047] In certain embodiments, the pulmonary disorder is pneumonia or pleural effusion. In certain embodiments, the pulmonary disorder is edema. In certain embodiments, the pulmonary disorder is bronchitis. In certain embodiments, the pulmonary disorder is chronic bronchitis. In certain embodiments, the pulmonary disorder is pneumonia.
[0048] Results produced by the method The method may be further characterized according to the results produced by the method. For example, in certain embodiments, the patient experiences at least a 25% reduction in symptoms from the lung disorder within one week from the first day of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in symptoms from the lung disorder within one week from the first day of the treatment method.
[0049] B. Methods for Treating Neurodegenerative Disorders Another aspect of the present invention provides methods for treating neurodegenerative disorders, which are described in more detail below.
[0050] First Method Another aspect of the present invention is a method for treating a neurodegenerative disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0051] Second Method Another aspect of the present invention is a method for treating a neurodegenerative disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On at least 5 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On at least 10 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0052] In certain embodiments, step (b) is performed at least 20 days after day 1. In certain embodiments, step (b) is performed at least 30 days after day 1. In certain embodiments, step (b) is performed about 30 days after day 1. In certain embodiments, step (b) is performed about 25 to about 35 days after day 1. In certain embodiments, step (c) is performed at least 50 days after day 1. In certain embodiments, step (c) is performed at least 60 days after day 1. In certain embodiments, step (c) is performed about 50 to about 70 days after day 1. In certain embodiments, step (c) is performed about 60 days after day 1.
[0053] In a more specific embodiment, the present invention provides a method for treating a neurodegenerative disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0054] In a more specific embodiment, the present invention provides a method for treating a neurological disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat the neurological disorder: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0055] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0056] In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0057] In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0058] In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0059] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof over a duration of about 45 minutes a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cells containing about 100 million to about 1 billion cells; ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 1 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0060] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0061] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a neurodegenerative disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0062] In certain embodiments, the first injectable pharmaceutical composition contains about 300 mL to about 450 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 150 mL to about 250 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 250 mL to about 300 mL of saline.
[0063] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 300 mL to about 450 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0064] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0065] Additional Exemplary Features of the First and Second Methods for Treating a Neurodegenerative Disorder Additional exemplary features that can characterize the first and second methods for treating neurodegenerative disorders described herein are provided below, including, for example, features of the injectable pharmaceutical compositions, the neurodegenerative disorders treated, and the results produced by the methods. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0066] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical compositions, such as the number of stromal vascular cell population cells in the injectable pharmaceutical compositions, the volume of saline in the injectable pharmaceutical compositions, and the total volume of the injectable pharmaceutical compositions. For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 800 million cells. In certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 400 million cells, about 400 million to about 600 million cells, or about 600 million to about 800 million cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 500 million to about 2.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 1 billion cells, about 1 billion to about 2 billion cells, or about 2 billion to about 2.5 billion cells.
[0067] In certain embodiments, the first injectable pharmaceutical composition contains about 380 mL to about 490 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 180 mL to about 240 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 150 mL to about 195 mL of saline.
[0068] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 400 mL to about 600 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0069] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0070] In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 10 mL / min.
[0071] Additional Method Steps The method may be further characterized according to additional steps the method further comprises. For example, in certain embodiments, the method further comprises intravenously administering saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 25, 50, 75, 100, 125, or 150 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient over a duration of about 25 minutes before intravenously administering the first injectable pharmaceutical composition to the patient.
[0072] In certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0073] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1 or within three days prior to day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1.
[0074] Neurodegenerative diseases treated The method may be further characterized according to the neurodegenerative disorder being treated. For example, in certain embodiments, the neurodegenerative disorder is multiple sclerosis. In certain embodiments, the neurodegenerative disorder is amyotrophic lateral sclerosis. In certain embodiments, the neurodegenerative disorder is dementia. In certain embodiments, the neurodegenerative disorder is Parkinson's disease.
[0075] Results produced by the method The method may be further characterized according to the results produced by the method. For example, in certain embodiments, the patient experiences at least a 25% reduction in symptoms from the neurodegenerative disorder within three months after the first day of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in symptoms from the neurodegenerative disorder within three months after the first day of the treatment method.
[0076] C. Methods for Treating Brain Injury and Mental Illness Another aspect of the present invention provides methods for treating brain injuries and psychiatric disorders, which are described in more detail below.
[0077] First Method One aspect of the present invention is a method for treating a disorder selected from the group consisting of brain injury and psychiatric disorders, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0078] Second Method Another aspect of the present invention is a method for treating a disorder selected from the group consisting of brain injury and psychiatric disorders, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On at least 5 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On at least 10 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0079] In certain embodiments, step (b) is performed at least 20 days after day 1. In certain embodiments, step (b) is performed at least 30 days after day 1. In certain embodiments, step (b) is performed about 30 days after day 1. In certain embodiments, step (b) is performed about 25 to about 35 days after day 1. In certain embodiments, step (c) is performed at least 50 days after day 1. In certain embodiments, step (c) is performed at least 60 days after day 1. In certain embodiments, step (c) is performed about 50 to about 70 days after day 1. In certain embodiments, step (c) is performed about 60 days after day 1.
[0080] In a more specific embodiment, the present invention provides a method for treating a disorder selected from the group consisting of brain injury and psychiatric disorders, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0081] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0082] In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0083] In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0084] In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0085] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cells containing about 250 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0086] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0087] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0088] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 300 mL to about 500 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 250 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 250 mL.
[0089] Additional Exemplary Features of the First and Second Methods for Treating Brain Injury and Psychiatric Disorders Additional exemplary features that can characterize the first and second methods for treating brain injury and psychiatric disorders described herein are provided below, including, for example, features of the injectable pharmaceutical composition, the brain injury and psychiatric disorders treated, and the results produced by the methods. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0090] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical composition, such as the number of cells of the stromal vascular cell population in the injectable pharmaceutical composition, the volume of saline in the injectable pharmaceutical composition, and the total volume of the injectable pharmaceutical composition.
[0091] For example, in certain embodiments, the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. In certain embodiments, the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 400 million cells, about 400 million to about 600 million cells, or about 600 million to about 800 million cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 1 billion cells, about 1 billion to about 2 billion cells, or about 2 billion to about 2.5 billion cells.
[0092] In certain embodiments, the first injectable pharmaceutical composition contains about 380 mL to about 490 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 180 mL to about 240 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 150 mL to about 195 mL of saline.
[0093] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 400 mL to about 600 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0094] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0095] In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 10 mL / min.
[0096] Additional Method Steps The method may be further characterized according to additional steps the method further comprises. For example, in certain embodiments, the method further comprises intravenously administering saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 25, 50, 75, 100, 125, or 150 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient over a duration of about 25 minutes before intravenously administering the first injectable pharmaceutical composition to the patient.
[0097] In certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0098] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1 or within three days prior to day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1.
[0099] Treating brain injuries and mental illnesses The method may be further characterized according to the brain injury and psychiatric disorder being treated. For example, in certain embodiments, the disorder is brain injury. In certain embodiments, the disorder is stroke. In certain embodiments, the disease is chronic traumatic encephalopathy. In certain embodiments, the disorder is traumatic brain injury. In certain embodiments, the disorder is a psychiatric disorder. In certain embodiments, the disorder is post-traumatic stress disorder. In certain embodiments, the disorder is anxiety disorder. In certain embodiments, the disorder is post-concussion syndrome.
[0100] Results produced by the method The method may be further characterized according to the results produced by the method. For example, in certain embodiments, the patient experiences at least a 25% reduction in symptoms from the disorder within three months after the first day of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in symptoms from the neurodegenerative disorder within three months after the first day of the treatment method.
[0101] D. Methods for Treating Metabolic Disorders Another aspect of the present invention provides methods for treating metabolic disorders, which are described in more detail below.
[0102] First Method One aspect of the present invention is a method for treating a metabolic disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0103] Second Method Another aspect of the present invention is a method for treating a metabolic disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On at least 5 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On at least 10 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. At least 20 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; e. On at least 40 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0104] In certain embodiments, step (b) is performed at least 10 days after day 1. In certain embodiments, step (b) is performed at least 14 days after day 1. In certain embodiments, step (b) is performed about 14 days after day 1. In certain embodiments, step (b) is performed about 10 to about 20 days after day 1. In certain embodiments, step (c) is performed at least 20 days after day 1. In certain embodiments, step (c) is performed at least 35 days after day 1. In certain embodiments, step (c) is performed about 35 days after day 1. In certain embodiments, step (c) is performed about 25 to about 45 days after day 1. In certain embodiments, step (d) is performed at least 40 days after day 1. In certain embodiments, step (d) is performed at least 65 days after day 1. In certain embodiments, step (d) is performed about 65 days after day 1. In certain embodiments, step (d) is performed about 55 to about 75 days after day 1. In certain embodiments, step (e) is performed at least 65 days after day 1. In certain embodiments, step (e) is performed at least 95 days after day 1. In certain embodiments, step (e) is performed about 95 days after day 1. In certain embodiments, step (e) is performed about 80 to about 110 days after day 1.
[0105] In a more specific embodiment, the present invention provides a method for treating a metabolic disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat the metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. A second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0106] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0107] In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0108] In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0109] In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0110] In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0111] In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (e), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (e), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (e), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0112] In certain embodiments, the methods comprise intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0113] In certain embodiments, the methods comprise intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0114] In certain embodiments, the methods comprise intravenously administering a population of stromal vascular cells to a patient in need thereof to treat a metabolic disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0115] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 250 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 100 mL to about 250 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL.
[0116] Additional Exemplary Features of the First and Second Methods for Treating a Metabolic Disorder Additional exemplary features that may characterize the first and second methods for treating metabolic disorders described herein are provided below, including, for example, features of the injectable pharmaceutical compositions, the metabolic disorders treated, and the results produced by the methods. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0117] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical compositions, such as the number of stromal vascular cell population cells in the injectable pharmaceutical compositions, the volume of saline in the injectable pharmaceutical compositions, and the total volume of the injectable pharmaceutical compositions. For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 800 million cells. In certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 400 million cells, about 400 million to about 600 million cells, or about 600 million to about 800 million cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 500 million to about 2.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 1 billion cells, about 1 billion to about 2 billion cells, or about 2 billion to about 2.5 billion cells.
[0118] In certain embodiments, the first injectable pharmaceutical composition contains about 380 mL to about 490 mL of saline. In certain embodiments, the first injectable pharmaceutical composition contains about 150 mL to about 195 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 180 mL to about 240 mL of saline.
[0119] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 400 mL to about 600 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0120] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0121] In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 10 mL / min.
[0122] Additional Method Steps The method may be further characterized according to additional steps the method further comprises. For example, in certain embodiments, the method further comprises intravenously administering saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 25, 50, 75, 100, 125, or 150 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient over a duration of about 25 minutes before intravenously administering the first injectable pharmaceutical composition to the patient.
[0123] In certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0124] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1 or within three days prior to day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1.
[0125] Metabolic disorders treated The method may be further characterized according to the metabolic disorder to be treated.For example, in certain embodiments, the metabolic disorder is diabetes.In certain embodiments, the metabolic disorder is type I diabetes, type 2 diabetes, or metabolic syndrome.In certain embodiments, the metabolic disorder is type I diabetes or type 2 diabetes.In certain embodiments, the metabolic disorder is type I diabetes.In certain embodiments, the metabolic disorder is type 2 diabetes.In certain embodiments, the metabolic disorder is metabolic syndrome.
[0126] Results produced by the method The methods may be further characterized according to the results produced by the methods. For example, in certain embodiments, the patient experiences at least a 25% reduction in symptoms from the disorder within four months after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in symptoms from the disorder within four months after day 1 of the treatment method.
[0127] E. Methods for Treating Pain Another aspect of the present invention provides methods for treating pain, which are described in more detail below.
[0128] First Method One aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0129] Second Method Another aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On at least 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On at least 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. The method as described above, wherein a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0130] In certain embodiments, step (b) is performed at least 50 days after day 1. In certain embodiments, step (b) is performed at least 70 days after day 1. In certain embodiments, step (b) is performed at least 90 days after day 1. In certain embodiments, step (b) is performed about 90 days after day 1. In certain embodiments, step (b) is performed about 70 to about 110 days after day 1. In certain embodiments, step (c) is performed at least 90 days after day 1. In certain embodiments, step (c) is performed at least 150 days after day 1. In certain embodiments, step (c) is performed at least 210 days after day 1. In certain embodiments, step (c) is performed about 210 days after day 1. In certain embodiments, step (c) is performed about 180 to about 240 days after day 1.
[0131] In a more specific embodiment, the present invention provides a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat pain: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. The method as described above, wherein a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0132] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0133] In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0134] In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0135] In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0136] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0137] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0138] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL to about 350 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 250 mL to about 350 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 250 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL.
[0139] Additional Exemplary Features of the First and Second Methods for Treating Pain Additional exemplary features that may characterize the first and second methods for treating pain described herein are provided below, including, for example, the characteristics of the injectable pharmaceutical composition, the type of pain treated, and the results produced by the method. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0140] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical compositions, such as the number of stromal vascular cell population cells in the injectable pharmaceutical compositions, the volume of saline in the injectable pharmaceutical compositions, and the total volume of the injectable pharmaceutical compositions. For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 800 million cells. In certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 400 million cells, about 400 million to about 600 million cells, or about 600 million to about 800 million cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 500 million to about 2.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 1 billion cells, about 1 billion to about 2 billion cells, or about 2 billion to about 2.5 billion cells.
[0141] In certain embodiments, the first injectable pharmaceutical composition contains about 380 mL to about 490 mL of saline. In certain embodiments, the first injectable pharmaceutical composition contains about 150 mL to about 195 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 180 mL to about 240 mL of saline.
[0142] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 400 mL to about 600 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0143] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0144] In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 10 mL / min.
[0145] Additional Method Steps The method may be further characterized according to additional steps the method further comprises. For example, in certain embodiments, the method further comprises intravenously administering saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 25, 50, 75, 100, 125, or 150 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient over a duration of about 25 minutes before intravenously administering the first injectable pharmaceutical composition to the patient.
[0146] In certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0147] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1 or within three days prior to day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1.
[0148] Administration at or near the site of pain The method may be further characterized according to the characteristics of the administration of one or more doses of the third pharmaceutical composition at or near the site of pain. For example, in certain embodiments, the method further comprises administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing 100 million to about 1 billion cells. In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing 100 million to about 500 million cells. In certain embodiments, the cells derived from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 1 million / mL to about 300 million / mL. In certain embodiments, the cells derived from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 150 million / mL to about 300 million / mL. In certain embodiments, the cells from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 200 million / mL to about 300 million / mL. In certain embodiments, the cells from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 250 million / mL to about 350 million / mL.
[0149] Preferably, the first or second injectable pharmaceutical composition is administered intravenously followed by one or more doses of the third pharmaceutical composition at or near the pain site.By administering one or more doses of the third pharmaceutical composition at or near the pain site, the stem cells from the stromal vascular cell population administered at or near the pain site by the administration of one or more doses of the third pharmaceutical composition are more likely to remain at or near the pain site when the third pharmaceutical composition is administered after the intravenous administration of the first or second injectable pharmaceutical composition.
[0150] In certain embodiments, the third pharmaceutical composition is administered by injection into tissue at or near the site of pain.
[0151] In certain embodiments, the dose of the third pharmaceutical composition ranges from about 0.5 mL to about 3 mL. In certain embodiments, the dose of the third pharmaceutical composition ranges from about 1 mL to about 2 mL.
[0152] In certain embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 doses of the third pharmaceutical composition are administered to the patient daily. In certain embodiments, 1, 2, 3, or 4 doses of the third pharmaceutical composition are administered to the patient daily.
[0153] In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 5 million to about 200 million cells. In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 5 million to about 1 billion cells. In certain embodiments, the cells from the stromal vascular cells are present in the third injectable pharmaceutical composition at a concentration of about 5 million cells / mL to about 10 million cells / mL.
[0154] In certain embodiments, 50 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 40 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 20 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 10 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day.
[0155] In certain embodiments, 5 mL or less of the third injectable pharmaceutical composition is administered to any one location of the patient on any one day. In certain embodiments, 2 mL or less of the third injectable pharmaceutical composition is administered to any one location of the patient on any one day.
[0156] In certain embodiments, the third injectable pharmaceutical composition is administered to a patient in an amount of about 0.1 mL to about 1 mL, about 1 mL to about 2 mL, about 2 mL to about 5 mL, about 5 mL to about 10 mL, about 10 mL to about 15 mL, about 15 mL to about 25 mL, about 25 mL to about 35 mL, or about 35 mL to about 50 mL on any one day. In certain embodiments, the third injectable pharmaceutical composition is administered to a patient in an amount of about 0.1 mL to about 1 mL, or about 1 mL to about 2 mL on any one day.
[0157] In certain embodiments, a local anesthetic other than a caine analgesic is administered to the patient at the location(s) that will receive the third injectable pharmaceutical composition prior to administering the third injectable pharmaceutical composition to the patient.
[0158] In certain embodiments, the method does not include the further step of administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells.
[0159] Types of pain treated The methods may be further characterized according to the type of pain being treated. For example, in certain embodiments, the pain is chronic pain. In certain embodiments, the pain is acute pain. In certain embodiments, the pain is neuropathic pain. In certain embodiments, the pain is non-neuropathic pain.
[0160] In certain embodiments, the pain is joint pain. In certain embodiments, the pain is arthritic joint pain. In certain embodiments, the pain is osteoarthritic joint pain. In certain embodiments, the joint is a knee joint, ankle joint, hip joint, shoulder joint, elbow joint, wrist joint, or finger joint. In certain embodiments, the joint is a knee joint. In certain embodiments, the joint is an ankle joint. In certain embodiments, the joint is a hip joint. In certain embodiments, the joint is a shoulder joint. In certain embodiments, the joint is an elbow joint. In certain embodiments, the joint is a wrist joint. In certain embodiments, the joint is a finger joint.
[0161] In certain embodiments, the pain is pain caused by lupus. In certain embodiments, the pain is pain caused by fibromyalgia or chronic inflammatory demyelinating neuropathy. In certain embodiments, the pain is pain caused by fibromyalgia. In certain embodiments, the pain is pain caused by chronic inflammatory demyelinating neuropathy. In certain embodiments, the pain is pain caused by arthritis.
[0162] In certain embodiments, the pain is nociceptive pain, inflammatory pain, or functional pain. In certain embodiments, the pain is nociceptive pain. In certain embodiments, the pain is inflammatory pain. In certain embodiments, the pain is functional pain.
[0163] Results produced by the method The methods may be further characterized according to the results produced by the methods. For example, in certain embodiments, the patient experiences at least a 25% reduction in pain within nine months after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in pain within nine months after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 25% reduction in pain within one month after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in pain within one month after day 1 of the treatment method.
[0164] The pain relief experienced by the patient can be assessed using procedures described in the literature, such as the Patient Global Impression of Change (PGIC, change from baseline in the index knee on a 7-point scale: 1 = very improved, 7 = very worse, with a score of 1 or 2 indicating significant improvement), the Patient-specific Functional Scale (PSFS, rating important activities that are difficult to perform due to pain in the index knee on a 0-10 scale: 0 = able to do, 10 = unable to do), and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) B stiffness subscale and WOMAC C function subscale.
[0165] The methods may be further characterized according to the duration of pain reduction. For example, in certain embodiments, the methods are characterized by achieving pain reduction for at least 3 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 4 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 5 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 6 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 7 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 8 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 9 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 10 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 11 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 12 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 4 and 6 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 6 and 9 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 6 and 12 months. In certain embodiments, the method is characterized by achieving pain relief for a period of 9 to 12 months. In certain embodiments, the method is characterized by achieving pain relief for a period of 12 to 18 months.
[0166] Third Method Another aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 120 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The above method is provided, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0167] Fourth Method Another aspect of the present invention is a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On at least 5 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On at least 15 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. At least 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; e. On at least 50 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. The method as described above, wherein a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0168] In certain embodiments, step (b) is performed at least 15 days after day 1. In certain embodiments, step (b) is performed at least 30 days after day 1. In certain embodiments, step (b) is performed about 30 days after day 1. In certain embodiments, step (b) is performed about 20 to about 40 days after day 1. In certain embodiments, step (c) is performed at least 40 days after day 1. In certain embodiments, step (c) is performed at least 50 days after day 1. In certain embodiments, step (c) is performed at least 60 days after day 1. In certain embodiments, step (c) is performed about 60 days after day 1. In certain embodiments, step (c) is performed about 45 to about 75 days after day 1. In certain embodiments, step (d) is performed at least 45 days after day 1. In certain embodiments, step (d) is performed at least 65 days after day 1. In certain embodiments, step (d) is performed at least 75 days after day 1. In certain embodiments, step (d) is performed at least 90 days after day 1. In certain embodiments, step (d) is performed about 90 days after day 1. In certain embodiments, step (d) is performed about 70 to about 110 days after day 1. In certain embodiments, step (e) is performed at least 80 days after day 1. In certain embodiments, step (e) is performed at least 100 days after day 1. In certain embodiments, step (e) is performed at least 120 days after day 1. In certain embodiments, step (e) is performed about 120 days after day 1. In certain embodiments, step (e) is performed about 100 to about 140 days after day 1.
[0169] In a more specific embodiment, the present invention provides a method for treating pain, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat pain: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; e. On approximately 120 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by ii. The method as described above, wherein a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0170] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0171] In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (a), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (a), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0172] In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (b), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (b), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0173] In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (c), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (c), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0174] In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (d), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step (d), the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0175] In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 70 minutes, 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 25 minutes to about 65 minutes, or about 40 minutes to about 50 minutes. In certain embodiments, in step (e), the first injectable pharmaceutical composition is intravenously administered over about 45 minutes. In certain embodiments, in step (e), the second injectable pharmaceutical composition is intravenously administered over about 60 minutes, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or less than 10 minutes. In certain embodiments, in step (e), the second injectable pharmaceutical composition is intravenously administered over about 10 minutes to about 60 minutes, or about 20 minutes to about 40 minutes. In certain embodiments, in step TIFF2023549530000001.tif53, the second injectable pharmaceutical composition is administered intravenously over about 30 minutes.
[0176] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; e. On approximately 120 days after Day 1: iii. intravenously administering to a patient in need thereof an amount of about 200 mL of a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by iv. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; Stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate and without the use of enzymes or sonication probes.
[0177] In certain embodiments, the method comprises intravenously administering a population of stromal vascular cells to a patient in need thereof to treat pain according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 200 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; e. On approximately 120 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition in an amount of about 200 mL containing saline and an aliquot of stromal vascular cell population containing about 100 million to about 2 billion cells over a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 100 million to about 2 billion cells; Stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate and without the use of enzymes or sonication probes.
[0178] In certain embodiments, the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 2 billion cells.
[0179] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL to about 350 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 250 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 250 mL.
[0180] Additional Exemplary Features of the Third and Fourth Methods for Treating Pain Additional exemplary features that may characterize the third and fourth methods for treating pain described herein are provided below, including, for example, the characteristics of the injectable pharmaceutical composition, the type of pain treated, and the results produced by the method. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0181] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical compositions, such as the number of stromal vascular cell population cells in the injectable pharmaceutical compositions, the volume of saline in the injectable pharmaceutical compositions, and the total volume of the injectable pharmaceutical compositions. For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 800 million cells. In certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 200 million to about 400 million cells, about 400 million to about 600 million cells, or about 600 million to about 800 million cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cell population containing about 500 million to about 2.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 1 billion cells, about 1 billion to about 2 billion cells, or about 2 billion to about 2.5 billion cells.
[0182] In certain embodiments, the first injectable pharmaceutical composition contains about 380 mL to about 490 mL of saline. In certain embodiments, the first injectable pharmaceutical composition contains about 150 mL to about 195 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 180 mL to about 240 mL of saline.
[0183] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 400 mL to about 600 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 180 mL to about 220 mL. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 200 mL.
[0184] In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 500 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 250 mL to about 450 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 420 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 300 mL to about 400 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 200 mL to about 300 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 150 mL to about 200 mL.
[0185] In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 2 to about 10 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 5 mL / min. In certain embodiments, the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 10 mL / min.
[0186] Additional Method Steps The method may be further characterized according to additional steps the method further comprises. For example, in certain embodiments, the method further comprises intravenously administering saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 25, 50, 75, 100, 125, or 150 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering at least about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient before intravenously administering the first injectable pharmaceutical composition to the patient. In certain embodiments, the method further comprises intravenously administering about 100 mL of saline to the patient over a duration of about 25 minutes before intravenously administering the first injectable pharmaceutical composition to the patient.
[0187] In certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0188] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1 or within three days prior to day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1.
[0189] Administration at or near the site of pain The method may be further characterized according to the characteristics of administering one or more doses of a third pharmaceutical composition at or near the site of pain. For example, in certain embodiments, the method further comprises administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 100 million to about 1 billion cells. In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of a stromal vascular cell population containing about 100 million to about 500 million cells. In certain embodiments, the cells derived from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 150 million cells / mL to about 300 million cells / mL. In certain embodiments, the cells derived from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 1 million cells / mL to about 300 million cells / mL. In certain embodiments, the cells from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 200 million cells / mL to about 300 million cells / mL. In certain embodiments, the cells from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 250 million cells / mL to about 350 million cells / mL.
[0190] Preferably, the first or second injectable pharmaceutical composition is administered intravenously followed by one or more doses of the third pharmaceutical composition at or near the pain site.By administering one or more doses of the third pharmaceutical composition at or near the pain site, the stem cells from the stromal vascular cell population administered at or near the pain site by the administration of one or more doses of the third pharmaceutical composition are more likely to remain at or near the pain site when the third pharmaceutical composition is administered after the intravenous administration of the first or second injectable pharmaceutical composition.
[0191] In certain embodiments, the third pharmaceutical composition is administered by injection into tissue at or near the site of pain.
[0192] In certain embodiments, the dose of the third pharmaceutical composition ranges from about 0.5 mL to about 3 mL. In certain embodiments, the dose of the third pharmaceutical composition ranges from about 1 mL to about 2 mL.
[0193] In certain embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 doses of the third pharmaceutical composition are administered to the patient daily. In certain embodiments, 1, 2, 3, or 4 doses of the third pharmaceutical composition are administered to the patient daily.
[0194] In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 2 million to about 5 million cells. In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 2 million to about 5 million cells. In certain embodiments, the cells from the stromal vascular cells are present in the third injectable pharmaceutical composition at a concentration of about 5 million cells / mL to about 10 million cells / mL.
[0195] In certain embodiments, 50 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 40 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 20 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day. In certain embodiments, 10 mL or less of the third injectable pharmaceutical composition is administered to the patient on any one day.
[0196] In certain embodiments, 5 mL or less of the third injectable pharmaceutical composition is administered to any one location of the patient on any one day. In certain embodiments, 2 mL or less of the third injectable pharmaceutical composition is administered to any one location of the patient on any one day.
[0197] In certain embodiments, the third injectable pharmaceutical composition is administered to a patient in an amount of about 0.1 mL to about 1 mL, about 1 mL to about 2 mL, about 2 mL to about 5 mL, about 5 mL to about 10 mL, about 10 mL to about 15 mL, about 15 mL to about 25 mL, about 25 mL to about 35 mL, or about 35 mL to about 50 mL on any one day.
[0198] In certain embodiments, a local anesthetic other than a caine analgesic is administered to the patient at the location(s) that will receive the third injectable pharmaceutical composition prior to administering the third injectable pharmaceutical composition to the patient.
[0199] In certain embodiments, the method does not include the further step of administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells.
[0200] Types of pain treated The methods may be further characterized according to the type of pain being treated. For example, in certain embodiments, the pain is chronic pain. In certain embodiments, the pain is acute pain. In certain embodiments, the pain is neuropathic pain. In certain embodiments, the pain is non-neuropathic pain.
[0201] In certain embodiments, the pain is neck pain. In certain embodiments, the pain is lower back pain.
[0202] In certain embodiments, the pain is nociceptive pain, inflammatory pain, or functional pain. In certain embodiments, the pain is nociceptive pain. In certain embodiments, the pain is inflammatory pain. In certain embodiments, the pain is functional pain.
[0203] Results produced by the method The methods may be further characterized according to the results produced by the methods. For example, in certain embodiments, the patient experiences at least a 25% reduction in pain within six months after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in pain within six months after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 25% reduction in pain within one month after day 1 of the treatment method. In certain embodiments, the patient experiences at least a 50% reduction in pain within one month after day 1 of the treatment method.
[0204] The pain relief experienced by the patient can be assessed using procedures described in the literature, such as the Patient Global Impression of Change (PGIC, change from baseline in the index knee on a 7-point scale: 1 = very improved, 7 = very worse, with a score of 1 or 2 indicating significant improvement), the Patient-specific Functional Scale (PSFS, rating important activities that are difficult to perform due to pain in the index knee on a 0-10 scale: 0 = able to do, 10 = unable to do), and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) B stiffness subscale and WOMAC C function subscale.
[0205] The methods may be further characterized according to the duration of pain reduction. For example, in certain embodiments, the methods are characterized by achieving pain reduction for at least 3 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 4 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 5 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 6 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 7 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 8 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 9 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 10 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 11 months. In certain embodiments, the methods are characterized by achieving pain reduction for at least 12 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 4 and 6 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 6 and 9 months. In certain embodiments, the methods are characterized by achieving pain reduction for between 6 and 12 months. In certain embodiments, the method is characterized by achieving pain relief for a period of 9 to 12 months. In certain embodiments, the method is characterized by achieving pain relief for a period of 12 to 18 months.
[0206] F. Methods for Treating or Preventing Coronavirus Infection Another aspect of the present invention provides methods for the treatment or prevention of coronavirus infection, which are described in more detail below.
[0207] First Method One aspect of the present invention is a method for treating or preventing coronavirus infection in a patient, comprising intravenously administering a population of stromal vascular cells to said patient in need thereof according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; The method provides that the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes.
[0208] Second Method Another aspect of the present invention is a method for treating or preventing coronavirus infection in a patient, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule: a. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells, followed by b. intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; and c. intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; and d. A fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is administered intravenously to a patient in need thereof.
[0209] In certain embodiments, step (b) is performed at least one day after step (a). In certain embodiments, step (b) is performed one day after step (a). In certain embodiments, step (c) is performed at least one day after step (b). In certain embodiments, step (c) is performed one day after step (b). In certain embodiments, step (d) is performed at least one day after step (c). In certain embodiments, step (d) is performed one day after step (c).
[0210] In a more specific embodiment, the present invention provides a method for treating or preventing coronavirus infection in a patient, comprising intravenously administering to said patient in need thereof a population of stromal vascular cells according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; b. On the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells; d. Three days after day 1, a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells is intravenously administered to a patient in need thereof.
[0211] In certain embodiments, stromal vascular cells are obtained from adipose tissue through sonication of lipoaspirate tissue without the use of enzymes or sonication probes.
[0212] In some embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (a), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0213] In some embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (b), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0214] In some embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (c), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0215] In some embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 60 minutes, 45 minutes, 35 minutes, 25 minutes, 15 minutes, or less than 10 minutes. In certain embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 15 minutes to about 60 minutes, or about 25 minutes to about 45 minutes. In certain embodiments, in step (d), the injectable pharmaceutical composition is administered intravenously over about 35 minutes.
[0216] Additional Exemplary Features of the First and Second Methods for Treating or Preventing Coronavirus Infection Additional exemplary features that may characterize the first and second methods for treating or preventing a coronavirus infection described herein are provided below, including, for example, features of the injectable pharmaceutical composition, the type of coronavirus infection, and the results produced by the method. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0217] Injectable Pharmaceutical Compositions The method may be further characterized according to characteristics of the injectable pharmaceutical composition, such as the number of cells in the stromal vascular cell population in the injectable pharmaceutical composition, the volume of saline in the composition, and the total volume of the injectable pharmaceutical composition.
[0218] For example, in certain embodiments, a first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 900 million to about 1.5 billion cells. In certain embodiments, a second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. In certain embodiments, a third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. In certain embodiments, a fourth injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells.
[0219] In certain embodiments, the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline.
[0220] In certain embodiments, the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the third injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL.
[0221] Additional Method Steps The method may be further characterized according to the additional steps the method further comprises. For example, in certain embodiments, the method further comprises obtaining adipose tissue from the patient and processing it to provide the stromal vascular cells used in the first injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
[0222] In certain embodiments, the method is characterized in that saline is not intravenously administered to the patient immediately before the first injectable pharmaceutical composition is intravenously administered. Rapid intravenous administration of the first injectable pharmaceutical composition to the patient without immediately preceding intravenous administration of saline increases the concentration of stem cells from the patient's pulmonary interstitial vascular cell population.
[0223] Additional Features In certain embodiments, the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 900 million to about 1.5 billion cells. In certain embodiments, the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. In certain embodiments, the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. In certain embodiments, the fourth injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells.
[0224] In certain embodiments, the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL. In certain embodiments, the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the second injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the third injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. In certain embodiments, the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. In certain embodiments, the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL.
[0225] In certain embodiments, the method further comprises, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition.
[0226] In certain embodiments, the coronavirus infection is an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In certain embodiments, the coronavirus infection is an infection with a mutant strain of SARS-CoV-2. In certain embodiments, the coronavirus infection is an infection with a mutant strain of SARS-CoV-2 that has the spike protein of SARS-CoV-2. In certain embodiments, the coronavirus infection is an infection by SARS-CoV-2 or a variant thereof selected from B.1.617.2, cluster 5, lineage B.1.1.207, lineage B.1.1.7, variant of concern 202102 / 02, lineage B.1.1.317, lineage B.1.1.318, lineage B.1.351, lineage B.1.429, lineage B.1.525, lineage P.1 (also known as lineage B.1.1.28), D614G, E484K, N501Y, S477G / N, and P681H.
[0227] In certain embodiments, the patient is suffering from cognitive impairment (e.g., brain fog) due to coronavirus infection. In certain embodiments, the patient is immunocompromised. In certain embodiments, the method improves immune function, thereby promoting recovery from coronavirus infection. In certain embodiments, the method improves immune function to reduce the risk of contracting coronavirus infection. In certain embodiments, the method enhances repair of patient tissue damaged by coronavirus infection. In certain embodiments, the method enhances repair of patient tissue selected from lung tissue, kidney tissue, and pancreatic tissue damaged by coronavirus infection. In certain embodiments, the method enhances repair of fibrotic or scar tissue resulting from coronavirus infection. In certain embodiments, the method treats coronavirus infection.
[0228] G. Additional Exemplary Features of Treatment Methods Additional exemplary features that may characterize the therapeutic methods described herein are provided below, such as the characteristics of the stromal vascular cell population and patient for treatment. A more detailed description of such features is provided below. The present invention encompasses all permutations and combinations of these features.
[0229] Interstitial vascular cell population Percentage of viable cells in the stromal vascular cell population The method may be further characterized according to the percentage of viable cells in the stromal vascular cell population. For example, in certain embodiments, at least 80% of the cells in the stromal vascular cell population aliquot are viable. In certain embodiments, at least 85% of the cells in the stromal vascular cell population aliquot are viable. In certain embodiments, at least 90% of the cells in the stromal vascular cell population aliquot are viable. In certain embodiments, at least 95% of the cells in the stromal vascular cell population aliquot are viable. In certain embodiments, at least 98% of the cells in the stromal vascular cell population aliquot are viable.
[0230] Cell viability may be measured using a commercially available flow cytometer, such as the flow cytometer sold by Logos Biosystems.
[0231] Origin of stromal vascular cells The method may be further characterized according to the origin of the stromal vascular cells. For example, in certain embodiments, the stromal vascular cells are autologous stromal vascular cells. In certain embodiments, the stromal vascular cells are derived from adipose tissue obtained from the patient's abdomen. In certain embodiments, the stromal vascular cells are derived from adipose tissue according to the procedures described herein.
[0232] Characteristics of stromal vascular cells The present methods may be further characterized according to additional characteristics of the stromal vascular cell population. For example, in certain embodiments, the stromal vascular cell population comprises stem cells and other cells that express at least one protein selected from the group consisting of CD13, CD14, CD29, CD31, CD34, CD36, CD44, CD45, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD151, and SH3. In certain embodiments, the stromal vascular cell population comprises stem cells and other cells that express at least one protein selected from the group consisting of CD13, CD29, CD34, CD36, CD44, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD151, and SH3. In certain embodiments, the stromal vascular cell population comprises stem cells and other cells that express at least one protein selected from the group consisting of CD31, CD45, CD117, and CD146. In certain embodiments, the stromal vascular cell population may comprise stem cells and other cells that do not express CD56.
[0233] In certain embodiments, the stromal vascular cell population comprises stem cells and other cells that (i) express at least one protein selected from the group consisting of CD3, CD4, CD14, CD15, CD16, CD19, CD33, CD38, CD56, CD61, CD62e, CD62p, CD69, CD104, CD135, and CD144, and (ii) do not express any of CD3, CD4, CD14, CD15, CD16, CD19, CD33, CD38, CD56, CD61, CD62e, CD62p, CD69, CD104, CD135, and CD 144. In certain embodiments, the stromal vascular cell population comprises stem cells and other cells that express CD49d but do not express CD56.
[0234] In certain embodiments, the stromal vascular cell population comprises one or more of the following cell types: mesenchymal stem cells, hematopoietic cells, endothelial progenitor cells (EPCs), hematopoietic stem cells, platelets, Kupffer cells, osteoclasts, megakaryocytes, granulocytes, NK cells, endothelial precursor or progenitor cells, CD34+ cells, CD29+ cells, CD166+ cells, Thy-1+ or CD90+ stem cells, CD44+ cells; immune cells, e.g., monocytes, leukocytes, lymphocytes, B cells and T cells, NK cells, macrophages, neutrophil leukocytes, neutrophil leukocytes, and neutrophil leukocytes. immune and other cells that express one or more of the following markers: CD3, CD14 (macrophage marker), CD19, CD20 (B cell marker), CD29 (integrin unit), CD31 (endothelium, platelets, macrophages, Kupffer cells, granulocytes, T / NK cells, lymphocytes, megakaryocytes, osteoclasts, and neutrophils, etc.), CD44 (hyaluronic acid receptor), CD45 (B and T cell marker), CD56, CD73 (lymphocyte differentiation marker), and CD105.
[0235] In certain embodiments, the stromal vascular cell population comprises mesenchymal stem cells.
[0236] In certain embodiments, the stromal vascular cell population comprises cells that express any of the markers disclosed in the present application or any combination of these markers.
[0237] In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that express at least one protein selected from the group consisting of CD13, CD29, CD31, CD34, CD36, CD44, CD45, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD117, CD146, CD151, and SH3. In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that express at least one protein selected from the group consisting of CD13, CD29, CD34, CD36, CD44, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD151, and SH3. In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that express at least one protein selected from the group consisting of CD31, CD45, CD117, and CD146.
[0238] In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that (i) express at least one protein selected from the group consisting of CD13, CD29, CD31, CD34, CD36, CD44, CD45, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD117, CD146, CD151, and SH3, and (ii) do not express CD56. In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that (i) express at least one protein selected from the group consisting of CD13, CD29, CD34, CD36, CD44, CD49d, CD54, CD58, CD71, CD73, CD90, CD105, CD106, CD151, and SH3, and (ii) do not express CD56. In certain embodiments, the stromal vascular cell population comprises adipose-derived stem cells that (i) express at least one protein selected from the group consisting of CD31, CD45, CD117, and CD146, and (ii) do not express CD56.
[0239] In certain embodiments, the stromal vascular cell population comprises stem cells that express at least one protein selected from the group consisting of CD3, CD4, CD14, CD15, CD16, CD19, CD33, CD38, CD56, CD61, CD62e, CD62p, CD69, CD104, CD135, and CD144. In certain embodiments, the stromal vascular cell population comprises stem cells that do not express any of CD3, CD4, CD14, CD15, CD16, CD19, CD33, CD38, CD56, CD61, CD62e, CD62p, CD69, CD104, CD135, and CD144. In certain embodiments, the stromal vascular cell population comprises stem cells that express CD49d but do not express CD56.
[0240] In certain embodiments, the stromal vascular cell population comprises cells having the immunophenotypes CD31, CD34, and CD45. In certain embodiments, the stromal vascular cell population comprises cells having the immunophenotypes CD31, CD34, CD45, and CD73.
[0241] In certain embodiments, the stromal vascular cell population comprises mesenchymal stem cells. In certain embodiments, at least 25% of the cells in the stromal vascular cell population are mesenchymal stem cells. In certain embodiments, at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45% of the cells in the stromal vascular cell population are mesenchymal stem cells. In certain embodiments, about 10% to about 50% of the cells in the stromal vascular cell population are mesenchymal stem cells. In certain embodiments, about 30% to about 40% of the cells in the stromal vascular cell population are mesenchymal stem cells. In certain embodiments, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, or about 25% to about 25% of the cells in the stromal vascular cell population are mesenchymal stem cells.
[0242] In certain embodiments, the stromal vascular cells comprise cytokines.
[0243] Preservation of stromal vascular cells The method may be further characterized according to the preservation of the stromal vascular cell population cells. For example, in certain embodiments, the stromal vascular cell population cells are not preserved prior to use. In certain embodiments, the stromal vascular cell population cells are not preserved at temperatures below 0°C prior to use. In certain embodiments, the stromal vascular cell population cells are preserved prior to use in the method.
[0244] Stromal vascular cell group cells may be preserved by any suitable method known in the art (e.g., deep-freezing) and may be frozen at any temperature suitable for preserving cells. For example, in certain embodiments, stromal vascular cell group cells are frozen for storage. In certain embodiments, stromal vascular cell group cells are cryopreserved. In certain embodiments, stromal vascular cell group cells are frozen at about -20°C, about -80°C, about -120°C, about -130°C, about -135°C, about -140°C, about -150°C, about -160°C, about -170°C, about -180°C, about -190°C, or about -196°C. In certain embodiments, the stromal vascular cell group cells are frozen at a temperature less than about −20° C., about −80° C., about −120° C., about −130° C., about −135° C., about −140° C., about −150° C., about −160° C., about −170° C., about −180° C., about −190° C., or about −196° C. In certain embodiments, the stromal vascular cell group cells are frozen at any other temperature suitable for storing the cells. In certain embodiments, the stromal vascular cell group cells are stored in an appropriate container and prepared for storage to reduce the risk of cell damage and maximize the likelihood that the cells will survive thawing.
[0245] In certain embodiments, the stromal vascular cell population cells are stored at room temperature. In certain embodiments, the stromal vascular cell population cells are stored below room temperature but above freezing, for example, at about 4°C.
[0246] In certain embodiments, the stromal vascular cell population cells are harvested, washed in buffer or medium, counted, concentrated (by centrifugation), formulated in freezing medium (e.g., 90% FBS / 10% DMSO), or any combination of these steps. In certain embodiments, prior to cryopreserving the stromal vascular cell population cells, the stromal vascular cell population cells are isolated, centrifuged, and optionally frozen in a 10% DMSO / 90% FBS solution at a concentration of at least about 10 per mL. 4 In certain embodiments, the cryopreserved preparation comprising stromal vascular cell population cells may be substantially free of DMSO.
[0247] In certain embodiments, the cryopreserved stromal vascular (SVF) cell preparations described herein contain at least about 50,000-100,000 stromal vascular cell cells. In certain embodiments, the cryopreserved SVF cell preparations contain at least about 20,000-500,000 SVF cells. In certain embodiments, the cryopreserved SVF cell preparations contain at least about 5,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 75,000, 80,000, or 100,000 SVF cells. In certain embodiments, the cryopreserved SVF cell preparation comprises at least about 1,000, 2,000, 3,000, 4,000, 5,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 75,000, 80,000, 100,000, or 500,000 SVF cells. 4 , 2x10 4 , 3x10 4 , 4x10 4 , 5x10 4 , 6x10 4 , 7x10 4 , 8x10 4 , 9x10 4 , 1x10 5, 2x10 5 , 3x10 5 , 4x10 5 , 5x10 5 , 6x10 5 , 7x10 5 , 8x10 5 , 9x10 5 , 1x10 6 , 2x10 6 , 3x10 6 , 4x10 6 , 5x10 6 , 6x10 6 , 7x10 6 , 8x10 6 , 9x10 6 , 1x10 7 , 2x10 7 , 3x10 7 , 4x10 7 , 5x10 7 , 6x10 7 , 7x10 7 , 8x10 7 , 9x10 7 , 1x10 8 , 2x10 8 , 3x10 8 , 4x10 8 , 5x10 8 , 6x10 8 , 7x10 8 , 8x10 8 , 9x10 8 , 1x10 9 , 2x10 9 , 3x10 9 , 4x10 9 , 5x10 9 , 6x10 9 , 7x10 9 , 8x10 9 , or 9×10 9 Contains SVF cells.
[0248] In certain embodiments, the cryopreserved SVF cell preparation is mammalian SVF cells, hi certain embodiments, the cryopreserved SVF cell preparation is human SVF cells.
[0249] In certain embodiments, the cryopreserved SVF cell preparation contains at least about 50,000-100,000 SVF cells / mL. In certain embodiments, the cryopreserved SVF cell preparation contains at least about 20,000-500,000 SVF cells / mL. In certain embodiments, the cryopreserved SVF cell preparation contains at least about 5,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 75,000, 80,000, and 100,000 SVF cells / mL. In certain embodiments, the cryopreserved SVF cell preparation contains at least about 1,000, 2,000, 3,000, 4,000, 5,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 75,000, 80,000, 100,000, or 500,000 SVF cells / mL. 4 , 2x10 4 , 3x10 4 , 4x10 4 , 5x10 4 , 6x10 4 , 7x10 4 , 8x10 4 , 9x10 4 , 1x10 5 , 2x10 5 , 3x10 5 , 4x10 5 , 5x10 5 , 6x10 5 , 7x10 5 , 8x10 5 , 9x10 5 , 1x10 6 , 2x10 6 , 3x10 6 , 4x10 6 , 5x10 6 , 6x10 6 , 7x10 6 , 8x10 6 , 9x10 6 , 1x10 7 , 2x10 7, 3x10 7 , 4x10 7 , 5x10 7 , 6x10 7 , 7x10 7 , 8x10 7 , 9 10 x10 7 , 1x10 8 , 2x10 8 , 3x10 8 , 4x10 8 , 5x10 8 , 6x10 8 , 7x10 8 , 8x10 8 , 9x10 8 , 1x10 9 , 2x10 9 , 3x10 9 , 4x10 9 , 5x10 9 , 6x10 9 , 7x10 9 , 8x10 9 , or 9x10 9 , 1x10 10 , 2x10 10 , 3x10 10 , 4x10 10 , 5x10 10 , 6x10 10 , 7x10 10 , 8x10 10 or 9x10 10 Contains SVF cells / mL.
[0250] In certain embodiments, SVF cells recovered from cryopreservation maintain their viability and differentiation state. In certain embodiments, at least about 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the SVF cells maintain their viability and differentiation after cryopreservation. In certain embodiments, the SVF cells maintain their viability after being cryopreserved and stored for at least about 1, 2, 3, 4, 5, 6, or 7 days. In certain embodiments, the SVF cells maintain their viability after being cryopreserved and stored for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In certain embodiments, the SVF cells are cryopreserved and maintain their viability after storage for at least about 1, 2, 3, 4, 5, 6, or 7 years.
[0251] Patients for treatment The methods may be further characterized according to the patient for treatment. For example, in certain embodiments, the patient is a human. In certain embodiments, the patient is an adult human.
[0252] III. Interstitial vascular cell population preparation The stromal vascular cells used in the injectable pharmaceutical composition can be prepared as generally described below.
[0253] The adipose tissue in the container is subjected to sonication, with the container being placed in the sonicator on a cup horn located within the sonicator's water bath. The water bath maintains a constant temperature, and sonication is preferably performed using sonication pulses separated by pauses. After sonication, the contents of the container are mixed with saline, and the resulting mixture is centrifuged. After centrifugation, a plurality of cell pellets and a plurality of buffy coat cell layers are isolated from the oily supernatant, thereby producing a population of stromal vascular cells.
[0254] The procedure can be further characterized according to the characteristics of the sonication. In certain embodiments, the rest period in the sonication procedure is at least 10 seconds after each 1-minute sonication. In certain embodiments, the total sonication time is about 5 minutes. In certain embodiments, the sonication is performed at 70% to 90% of the amplitude of the sonicator operating at 20 kHz.
[0255] The procedure can be further characterized according to the characteristics of the centrifugation. In certain embodiments, the centrifugation is performed for a duration of at least about 3 minutes. In certain embodiments, the centrifugation is performed for a duration of at least 3 minutes. In certain embodiments, the centrifugation is performed at 3000 rpm.
[0256] In certain embodiments, the plurality of cell pellets and the plurality of buffy coat cell layers are filtered. In certain embodiments, the filtration is performed using a 60 μm filter.
[0257] In the step of mixing the contents of the container with saline after sonication, the method can further be characterized according to the amount of saline added to the container.In certain embodiments, the volume of saline added is approximately equal to the volume of the adipose tissue resulting from sonication.In certain embodiments, the aliquot of 25mL of adipose tissue resulting from sonication is mixed with the aliquot of 25mL of saline, and the resulting mixture is used for centrifugation.
[0258] Preferably, the container containing the adipose tissue is suspended above and does not contact the cup horn located within the sonicator's water bath. In certain embodiments, the container is placed within an adapter that maintains the container above and does not contact the cup horn located within the sonicator's water bath. In certain embodiments, the container is maintained at least 3 mm above the cup horn.
[0259] The procedure can be further characterized according to the characteristics of the sonication device. In certain embodiments, the water bath is maintained at about 20°C. In certain embodiments, the water bath is maintained at 20°C. Preferably, no sonication probe comes into contact with the adipose tissue. In certain embodiments, the container is a sonication bottle capable of holding at least 150 mL.
[0260] The procedure for obtaining stromal vascular cells from adipose tissue can be more specifically described by the following steps: placing a bottle containing adipose tissue in an ultrasonicator over a cup horn located within a water bath of the ultrasonicator, the bottle having a capacity to contain 150 mL of adipose tissue, the water bath being maintained at a constant temperature; The adipose tissue in the vessel is sonicated by pulses, the pulses being generated by inserting multiple pauses, and the sonicator is operated at an amplitude of 70% to 90% of that of a sonicator operating at 20 kHz. The adipose tissue resulting from the sonication is mixed with saline and the resulting mixture is centrifuged at 3000 rpm for a duration of at least 3 minutes; Discarding the oily supernatant from the mixture resulting from centrifugation, leaving a mixture of the cell pellet and buffy coat cell layer; The mixture of cell pellet and buffy coat cell layer is filtered, thereby generating a population of stromal vascular cells.
[0261] The procedure may be more particularly described according to one or more of the following characteristics: the pauses in the sonication steps are at least 10 seconds after each 1 minute of sonication, and the total sonication time is approximately 5 minutes in duration; Filtration is performed using a 60 μm filter Saline is mixed in equal volume with the adipose tissue resulting from sonication, The bottle containing the adipose tissue was suspended at least 3 mm above and out of contact with the cup horn located in the bath of the sonicator. The aquarium is maintained at a temperature of 20°C. The sonication of adipose tissue in a bottle is performed without a sonication probe in contact with said adipose tissue.
[0262] The methods of treatment described herein can be further characterized according to the procedures used to obtain the stromal vascular cells used in the methods of treatment, such as the stromal vascular cells present in an injectable pharmaceutical composition.
[0263] IV. Illustrative Embodiments Exemplary embodiments are listed below: 1. A method for treating a pulmonary disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat said pulmonary disorder: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to said patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to said patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to said patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing from about 300 million to about 2 billion cells over a duration of about 35 minutes; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 2. The method of embodiment 1, wherein the first injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing about 900 million to about 1.5 billion cells. 3. The method of embodiment 1 or 2, wherein the second injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 4. The method of any one of embodiments 1 to 3, wherein the third injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 5. The method of any one of embodiments 1 to 4, wherein the fourth injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 6. The method of any one of embodiments 1 to 5, wherein the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 7. The method of any one of embodiments 1 to 6, wherein the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL. 8. The method of any one of embodiments 1 to 7, wherein the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 9. The method of any one of embodiments 1 to 8, wherein the second injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 10. The method of any one of embodiments 1 to 9, wherein the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 11. The method of any one of embodiments 1 to 10, wherein the third injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 12. The method of any one of embodiments 1 to 11, wherein the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 13. The method of any one of embodiments 1 to 12, wherein the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 14. The method of any one of embodiments 1-13, further comprising the step of obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1. 15. The method of any one of embodiments 1-14, wherein said pulmonary disorder is chronic obstructive pulmonary disorder. 16. The method of any one of embodiments 1-14, wherein the pulmonary disorder is asthma. 17. The method of any one of embodiments 1-14, wherein the pulmonary disorder is bronchitis. 18. The method of any one of embodiments 1-14, wherein said pulmonary disorder is chronic bronchitis. 19. The method of any one of embodiments 1-14, wherein the pulmonary disorder is emphysema. 20. The method of any one of embodiments 1-14, wherein the pulmonary disorder is acute respiratory distress syndrome. 21. The method of any one of embodiments 1-14, wherein the lung disorder is infection with a coronavirus. 22. The method of any one of embodiments 1 to 14, wherein the lung disorder is infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 23. The method of any one of embodiments 1-14, wherein the pulmonary disorder is pneumonia or pleural effusion. 24. The method of any one of embodiments 1-23, wherein the patient experiences at least a 25% reduction in symptoms from the lung disorder within one week of day 1 of the treatment method. 25. The method of any one of embodiments 1-23, wherein the patient experiences at least a 50% reduction in symptoms from the lung disorder within one week of day 1 of the treatment method. 26. A method for treating a neurodegenerative disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat said neurodegenerative disorder: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 27. The method of embodiment 26, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 28. The method of embodiment 26 or 27, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 29. The method of any one of embodiments 26-28, wherein the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 30. The method of any one of embodiments 26 to 29, wherein the first injectable pharmaceutical composition has a volume of about 200 mL. 31. The method of any one of embodiments 26-30, wherein the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 32. The method of any one of embodiments 26 to 31, wherein the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. 33. The method of any one of embodiments 26-32, further comprising intravenously administering at least about 100 mL of saline to the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient. 34. The method of any one of embodiments 26-32, further comprising intravenously administering to the patient a volume of about 100 mL of saline over a duration of about 25 minutes prior to intravenously administering to the patient the first injectable pharmaceutical composition. 35. The method of any one of embodiments 26-34, further comprising, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 36. The method of any one of embodiments 26-34, further comprising the step of obtaining adipose tissue from the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, or within three days prior to day 1, and processing the tissue to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 37. The method of any one of embodiments 26-36, wherein the neurodegenerative disorder is multiple sclerosis. 38. The method of any one of embodiments 26-36, wherein the neurodegenerative disorder is amyotrophic lateral sclerosis. 39. The method of any one of embodiments 26-36, wherein the neurodegenerative disorder is dementia. 40. The method of any one of embodiments 26-36, wherein the neurodegenerative disorder is Parkinson's disease. 41. The method of any one of embodiments 26-40, wherein the patient experiences at least a 25% reduction in symptoms from the neurodegenerative disorder within 3 months after day 1 of the treatment method. 42. The method of any one of embodiments 26-40, wherein the patient experiences at least a 50% reduction in symptoms from the neurodegenerative disorder within 3 months after day 1 of the treatment method. 43. A method for treating a disorder selected from the group consisting of brain injury and psychiatric disorders, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof to treat said disorder according to the following administration schedule: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 44. The method of embodiment 43, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 45. The method of embodiment 43 or 44, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 46. The method of any one of embodiments 43-45, wherein the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 47. The method of any one of embodiments 43 to 46, wherein the first injectable pharmaceutical composition has a volume of about 200 mL. 48. The method of any one of embodiments 43-47, wherein the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 49. The method of any one of embodiments 43 to 48, wherein the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. 50. The method of any one of embodiments 43-49, further comprising intravenously administering at least about 100 mL of saline to the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient. 51. The method of any one of embodiments 43-49, further comprising intravenously administering to the patient a volume of about 100 mL of saline over a duration of about 25 minutes prior to said intravenously administering to the patient the first injectable pharmaceutical composition. 52. The method of any one of embodiments 43-51, further comprising, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 53. The method of any one of embodiments 43-51, further comprising the step of obtaining adipose tissue from the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, or within three days prior to day 1, and processing the tissue to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition that are injected intravenously into the patient on day 1. 54. The method of any one of embodiments 43-53, wherein the disorder is a brain injury. 55. The method of any one of embodiments 43-53, wherein the disorder is stroke. 56. The method of any one of embodiments 43-53, wherein the disease is chronic traumatic encephalopathy. 57. The method of any one of embodiments 43-53, wherein the disorder is traumatic brain injury. 58. The method of any one of embodiments 43-53, wherein the disorder is a psychiatric disorder. 59. The method of any one of embodiments 43-53, wherein the disorder is post-traumatic stress disorder. 60. The method of any one of embodiments 43-53, wherein the disorder is anxiety. 61. The method of any one of embodiments 43-53, wherein the disorder is post-concussion syndrome. 62. The method of any one of embodiments 43-61, wherein the patient experiences at least a 25% reduction in symptoms from the disorder within 3 months after day 1 of the treatment method. 63. The method of any one of embodiments 43-61, wherein the patient experiences at least a 50% reduction in symptoms from the disorder within 3 months after day 1 of the treatment method. 64. A method for treating a metabolic disorder, comprising intravenously administering a population of stromal vascular cells to a patient in need thereof according to the following administration schedule to treat said metabolic disorder: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 14 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 35 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 65 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 95 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 65. The method of embodiment 64, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 66. The method of embodiment 64 or 65, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 67. The method of any one of embodiments 64-66, wherein the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 68. The method of any one of embodiments 64 to 67, wherein the first injectable pharmaceutical composition has a volume of about 200 mL. 69. The method of any one of embodiments 64-68, wherein the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 70. The method of any one of embodiments 64-69, wherein the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. 71. The method of any one of embodiments 64-70, further comprising intravenously administering at least about 100 mL of saline to the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient. 72. The method of any one of embodiments 64-70, further comprising intravenously administering to the patient a volume of about 100 mL of saline over a duration of about 25 minutes prior to intravenously administering to the patient the first injectable pharmaceutical composition. 73. The method of any one of embodiments 64-72, further comprising, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 74. The method of any one of embodiments 64-72, further comprising the step of obtaining adipose tissue from the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, or within three days prior to day 1, and processing the tissue to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 75. The method of any one of embodiments 64-74, wherein the metabolic disorder is diabetes. 76. The method of any one of embodiments 64-74, wherein the metabolic disorder is type 1 diabetes, type 2 diabetes, or metabolic syndrome. 77. The method of any one of embodiments 64-76, wherein the patient experiences at least a 25% reduction in symptoms from the disorder within 4 months after day 1 of the treatment method. 78. The method of any one of embodiments 64-76, wherein the patient experiences at least a 50% reduction in symptoms from the disorder within 4 months after day 1 of the treatment method. 79. A method for treating pain, comprising intravenously administering to a patient in need thereof a population of stromal vascular cells according to the following administration schedule to treat said pain: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 210 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to a patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 80. The method of embodiment 79, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 81. The method of embodiment 79 or 80, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 82. The method of any one of embodiments 79-81, wherein the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 83. The method of any one of embodiments 79-82, wherein the first injectable pharmaceutical composition has a volume of about 200 mL. 84. The method of any one of embodiments 79-83, wherein the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 85. The method of any one of embodiments 79 to 84, wherein the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. 86. The method of any one of embodiments 79-85, further comprising intravenously administering at least about 100 mL of saline to the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient. 87. The method of any one of embodiments 79 to 85, further comprising intravenously administering to the patient a volume of about 100 mL of saline over a duration of about 25 minutes prior to intravenously administering to the patient the first injectable pharmaceutical composition. 88. The method of any one of embodiments 79 to 87, further comprising, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 89. The method of any one of embodiments 79-87, further comprising the step of obtaining adipose tissue from the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, or within three days prior to day 1, and processing the tissue to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 90. The method of any one of embodiments 79-89, further comprising administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 91. Embodiment 90, wherein the third injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 92. Embodiment 90 or 91, wherein cells from said stromal vascular cell population are present in said third injectable pharmaceutical composition at a concentration of about 1 million cells / mL to about 10 million cells / mL. 93. The method of any one of embodiments 90-92, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 50 mL on any one day. 94. The method of any one of embodiments 90-92, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 40 mL on any one day. 95. The method of any one of embodiments 90-92, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 20 mL on any one day. 96. The method of any one of embodiments 90-92, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 10 mL on any one day. 97. The method of any one of embodiments 90-96, wherein 5 mL or less of the third injectable pharmaceutical composition is administered to any one location in the patient on any one day. 98. The method of any one of embodiments 90-96, wherein 2 mL or less of the third injectable pharmaceutical composition is administered to any one location in the patient on any one day. 99. The method of any one of embodiments 90-98, wherein a local anesthetic other than a cain analgesic is administered to the patient at the location(s) that will receive the third injectable pharmaceutical composition prior to administering the third injectable pharmaceutical composition to the patient. 100. The method of any one of embodiments 79-99, wherein the pain is chronic pain. 101. The method of any one of embodiments 79-99, wherein the pain is acute pain. 102. The method of any one of embodiments 79-99, wherein the pain is neuropathic pain. 103. The method of any one of embodiments 79-99, wherein the pain is non-neuropathic pain. 104. The method of any one of embodiments 79-99, wherein the pain is joint pain. 105. The method of any one of embodiments 79-99, wherein the pain is arthritic joint pain. 106. The method of any one of embodiments 79-99, wherein the pain is osteoarthritis pain. 107. The method of any one of embodiments 103 to 106, wherein the joint is a knee joint, ankle joint, hip joint, shoulder joint, elbow joint, wrist joint, or finger joint. 108. The method of any one of embodiments 79-99, wherein the pain is lupus pain. 109. The method of any one of embodiments 79-99, wherein the pain is pain due to fibromyalgia or chronic inflammatory demyelinating neuropathy. 110. The method of any one of embodiments 79-99, wherein the pain is arthritis pain. 111. The method of any one of embodiments 79-99, wherein the pain is nociceptive pain, inflammatory pain, or functional pain. 112. The method of any one of embodiments 79-111, wherein the patient experiences at least a 25% reduction in pain within 9 months after day 1 of the treatment method. 113. The method of any one of embodiments 79-111, wherein the patient experiences at least a 50% reduction in pain within 9 months after day 1 of the treatment method. 114. A method for treating pain, comprising intravenously administering stromal vascular cells to a patient in need thereof according to the following administration schedule to treat said pain: a. On Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; b. On approximately 30 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; c. On approximately 60 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; d. Approximately 90 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; e. On approximately 120 days after Day 1: i. intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. intravenously administering to said patient in need thereof over a duration of about 30 minutes a second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 115. The method of embodiment 114, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 200 million to about 800 million cells. 116. The method of embodiment 114 or 115, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 500 million to about 2.5 billion cells. 117. The method of any one of embodiments 114-116, wherein the first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 118. The method of any one of embodiments 114 to 117, wherein the first injectable pharmaceutical composition has a volume of about 200 mL. 119. The method of any one of embodiments 114-118, wherein the second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min. 120. The method of any one of embodiments 114 to 119, wherein the second injectable pharmaceutical composition has a volume of about 200 mL to about 450 mL. 121. The method of any one of embodiments 114-120, further comprising intravenously administering at least about 100 mL of saline to the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient. 122. The method of any one of embodiments 114 to 120, further comprising intravenously administering to the patient a volume of about 100 mL of saline over a duration of about 25 minutes prior to intravenously administering to the patient the first injectable pharmaceutical composition. 123. The method of any one of embodiments 114 to 122, further comprising, prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 124. The method of any one of embodiments 114 to 122, further comprising the step of obtaining adipose tissue from the patient prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1, or within three days prior to day 1, and processing the tissue to provide a population of stromal vascular cells used in the first injectable pharmaceutical composition and the second injectable pharmaceutical composition administered intravenously to the patient on day 1. 125. The method of any one of embodiments 114-124, further comprising administering to the patient by injection at or near the site of pain a dose of a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 10 million to about 1 billion cells. 126. Embodiment 125, wherein the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 100 million to about 500 million cells. 127. The method of any one of embodiments 125 or 126, wherein the cells from the stromal vascular cell population are present in the third injectable pharmaceutical composition at a concentration of about 1 million cells / mL to about 300 million cells / mL. 128. The method of any one of embodiments 125-127, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 50 mL on any one day. 129. The method of any one of embodiments 125-127, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 40 mL on any one day. 130. The method of any one of embodiments 125-127, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 20 mL on any one day. 131. The method of any one of embodiments 125-127, wherein the third injectable pharmaceutical composition is administered to the patient in no more than 10 mL on any one day. 132. The method of any one of embodiments 125-131, wherein the third injectable pharmaceutical composition is administered to the patient at any one location in no more than 5 mL on any one day. 133. The method of any one of embodiments 125-131, wherein the third injectable pharmaceutical composition is administered to the patient at any one location in no more than 2 mL on any one day. 134. The method of any one of embodiments 125-133, wherein a local anesthetic other than a cain analgesic is administered to the patient at the location(s) that will receive the third injectable pharmaceutical composition prior to administering the third injectable pharmaceutical composition to the patient. 135. The method of any one of embodiments 114-134, wherein the pain is chronic pain. 136. The method of any one of embodiments 114-134, wherein the pain is acute pain. 137. The method of any one of embodiments 114-134, wherein the pain is neuropathic pain. 138. The method of any one of embodiments 114-134, wherein the pain is non-neuropathic pain. 139. The method of any one of embodiments 114-134, wherein the pain is neck pain. 140. The method of any one of embodiments 114-134, wherein the pain is lower back pain. 141. The method of any one of embodiments 114-134, wherein the pain is nociceptive pain, inflammatory pain, or functional pain. 142. The method of any one of embodiments 114-141, wherein the patient experiences at least a 25% reduction in pain within 6 months after day 1 of the treatment method. 143. The method of any one of embodiments 114-141, wherein the patient experiences at least a 50% reduction in pain within 6 months after day 1 of the treatment method. 144. The method of any one of embodiments 1-143, wherein at least 80% of the cells in the aliquot of stromal vascular cells are viable. 145. The method of any one of embodiments 1-143, wherein at least 85% of the cells in the aliquot of stromal vascular cells are viable. 146. The method of any one of embodiments 1-143, wherein at least 90% of the cells in the aliquot of stromal vascular cells are viable. 147. The method of any one of embodiments 1-143, wherein at least 95% of the cells in the aliquot of stromal vascular cells are viable. 148. The method of any one of embodiments 1-143, wherein at least 98% of the cells in the aliquot of stromal vascular cells are viable. 149. The method of any one of embodiments 1-148, wherein the stromal vascular cells are autologous stromal vascular cells. 150. The method of any one of embodiments 1-148, wherein the stromal vascular cells are derived from adipose tissue obtained from the patient's abdomen. 151. The method of any one of embodiments 1-150, wherein the patient is an adult human. 152. The stromal vascular cell population is treated by the following procedure without using an enzyme or an ultrasonic treatment probe: a. subjecting a container containing adipose tissue to sonication, wherein the container is placed in a sonicator over a cup horn located within a water bath of the sonicator, the water bath maintaining a constant temperature, and the sonication is performed using sonication pulses separated by multiple rest periods; b. after sonication in step (a), mixing the contents of the container with saline and centrifuging the resulting mixture; c. After centrifugation in step (b), isolating a plurality of cell pellets and a plurality of buffy coat cell layers from the oily supernatant, thereby generating the stromal vascular cell population. 153. The method of embodiment 152, wherein the rest periods in the sonication procedure are at least 10 seconds after each 1 minute of sonication. 154. The method of embodiment 152 or 153, wherein the total duration of the ultrasonic treatment is about 5 minutes. 155. A method according to any one of embodiments 152 to 154, wherein the ultrasonic treatment is carried out at 70% to 90% of the amplitude of an ultrasonic treatment device operating at 20 kHz. 156. The method of any one of embodiments 152-155, wherein the centrifugation is carried out for a duration of at least about 3 minutes. 157. The method of any one of embodiments 152 to 155, wherein the centrifugation is performed for a duration of at least 3 minutes. 158. The method of any one of embodiments 152-157, wherein the centrifugation is performed at 3000 rpm. 159. A method according to any one of embodiments 152 to 158, wherein a plurality of cell pellets and a plurality of buffy coat cell layers are subjected to filtration. 160. The method of embodiment 159, wherein the filtration is performed using a 60 μm filter. 161. The method of any one of embodiments 152-160, wherein the container is maintained at least 3 mm above the cup horn of the ultrasonic processor. 162. The method of any one of embodiments 152-161, wherein the water bath is maintained at a temperature of about 20°C. 163. A method for treating or preventing coronavirus infection in a patient, comprising intravenously administering to said patient in need thereof a population of stromal vascular cells according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; The method, wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes. 164. The method of embodiment 163, wherein the first injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 900 million to about 1.5 billion cells. 165. The method of embodiment 163 or 164, wherein the second injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 166. The method of any one of embodiments 163 to 165, wherein the third injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 167. The method of any one of embodiments 163 to 166, wherein the fourth injectable pharmaceutical composition contains saline and an aliquot of stromal vascular cells containing about 400 million to about 1 billion cells. 168. The method of any one of embodiments 163-167, wherein the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 169. The method of any one of embodiments 163 to 168, wherein the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL. 170. The method of any one of embodiments 163-169, wherein the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 171. The method of any one of embodiments 163-170, wherein the second injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 172. The method of any one of embodiments 163-171, wherein the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 173. The method of any one of embodiments 163-172, wherein the third injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 174. The method of any one of embodiments 163-173, wherein the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline. 175. The method of any one of embodiments 163-174, wherein the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL. 176. The method of any one of embodiments 163 to 175, further comprising the step of obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1. 177. The method of any one of embodiments 163 to 176, wherein the coronavirus infection is an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 178. The method of any one of embodiments 163 to 176, wherein the coronavirus infection is an infection with a mutant strain of SARS-CoV-2. 179. The method of any one of embodiments 163 to 176, wherein the coronavirus infection is an infection with a mutant strain of SARS-CoV-2 having the spike protein of SARS-CoV-2. 180. The method of any one of embodiments 163 to 176, wherein the coronavirus infection is an infection with SARS-CoV-2 or a variant thereof selected from B.1.617.2, cluster 5, lineage B.1.1.207, lineage B.1.1.7, variant of concern 202102 / 02, lineage B.1.1.317, lineage B.1.1.318, lineage B.1.351, lineage B.1.429, lineage B.1.525, lineage P.1 (also known as lineage B.1.1.28), D614G, E484K, N501Y, S477G / N, and P681H. 181. The method of any one of embodiments 163 to 180, wherein the patient suffers from cognitive impairment (e.g., brain fog) due to the coronavirus infection. 182. The method of any one of embodiments 163-181, wherein the patient is immunocompromised. 183. The method of any one of embodiments 163-182, wherein said method improves immune function, thereby promoting recovery from said coronavirus infection. 184. The method of any one of embodiments 163 to 183, wherein the method improves immune function, reducing the risk of contracting a coronavirus infection. 185. The method of any one of embodiments 163-184, wherein said method enhances repair of patient tissue damaged by said coronavirus infection. 186. The method of any one of embodiments 163-184, wherein said method enhances repair of patient tissue selected from lung tissue, kidney tissue, and pancreatic tissue damaged by said coronavirus infection. 187. The method of any one of embodiments 163-184, wherein the method enhances the repair of fibrous or scar tissue resulting from the coronavirus infection. 188. The method of any one of embodiments 163 to 187, wherein the method treats the coronavirus infection. 189. The method of any one of embodiments 163-188, wherein at least 80% of the cells in the aliquot of stromal vascular cells are viable. 190. The method of any one of embodiments 163-188, wherein at least 85% of the cells in the aliquot of stromal vascular cells are viable. 191. The method of any one of embodiments 163-188, wherein at least 90% of the cells in the aliquot of stromal vascular cells are viable. 192. The method of any one of embodiments 163-188, wherein at least 95% of the cells in the aliquot of stromal vascular cells are viable. 193. The method of any one of embodiments 163-188, wherein at least 98% of the cells in the aliquot of stromal vascular cells are viable. 194. The method of any one of embodiments 163-193, wherein the stromal vascular cells are autologous stromal vascular cells. 195. The method of any one of embodiments 163-193, wherein the stromal vascular cells are derived from adipose tissue obtained from the patient's abdomen. 196. The method of any one of embodiments 163-195, wherein the patient is an adult human. 197. The stromal vascular cell population is cultured by the following procedure without using an enzyme or an ultrasonication probe: a. subjecting a container containing adipose tissue to sonication, wherein the container is placed in a sonicator over a cup horn located within a water bath of the sonicator, the water bath maintaining a constant temperature, and the sonication is performed using sonication pulses separated by multiple rest periods; b. after sonication in step (a), mixing the contents of the container with saline and centrifuging the resulting mixture; c. After centrifugation in step (b), isolating a plurality of cell pellets and a plurality of buffy coat cell layers from the oily supernatant, thereby generating the stromal vascular cell population. 198. The method of embodiment 197, wherein the rest periods in the sonication procedure are at least 10 seconds after each 1 minute of sonication. 199. The method of embodiment 197 or 198, wherein the total duration of sonication is about 5 minutes. 200. The method of any one of embodiments 197-199, wherein the sonication is performed at an amplitude of 70% to 90% of the sonicator operating at 20 kHz. 201. The method of any one of embodiments 197-200, wherein the centrifugation is carried out for a duration of at least about 3 minutes. 202. The method of any one of embodiments 197-200, wherein the centrifugation is carried out for a duration of at least 3 minutes. 203. The method of any one of embodiments 197-200, wherein the centrifugation is performed at 3000 rpm. 204. The method of any one of embodiments 197-201, wherein the plurality of cell pellets and the plurality of buffy coat cell layers are subjected to filtration. 205. The method of embodiment 204, wherein the filtering is performed using a 60 μm filter. 206. The method of any one of embodiments 197-205, wherein the container is maintained at least 3 mm above the cup horn of the ultrasonic processor. 207. The method of any one of embodiments 197-206, wherein the water bath is maintained at a temperature of about 20°C.
[0264] V. Compositions for Medical Use The stromal vascular cell populations and pharmaceutical compositions can be used to treat the medical conditions described herein. The use may be in accordance with the methods described herein. For example, one aspect of the present invention provides a first injectable pharmaceutical composition, a second injectable pharmaceutical composition, a third injectable pharmaceutical composition, and a fourth injectable pharmaceutical composition for use in treating a pulmonary disorder according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; Stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate and without the use of enzymes or sonication probes.
[0265] The embodiments described herein in relation to methods of treatment may be applied in relation to pharmaceutical compositions for use.
[0266] VI. Preparation of pharmaceuticals The stromal vascular cell populations and pharmaceutical compositions described herein can be used in the preparation of medicaments for treating the medical conditions described herein. For example, one aspect of the present invention provides the use of a first injectable pharmaceutical composition, a second injectable pharmaceutical composition, a third injectable pharmaceutical composition, and a fourth injectable pharmaceutical composition described herein in the preparation of a medicament for treating a pulmonary disorder according to the following administration schedule: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, intravenously administering to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells over a duration of about 35 minutes; Stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate and without the use of enzymes or sonication probes.
[0267] The embodiments described herein in relation to methods of treatment may be applied in relation to pharmaceutical compositions for use in the preparation of a medicament.
[0268] VII. Medical Kit Another aspect of the present invention provides medical kits, e.g., comprising (i) a composition described herein and (ii) instructions for treating a medical disorder described herein according to the methods described herein. For example, a more specific embodiment of the present invention provides a medical kit, e.g., comprising (i) a composition described herein and (ii) instructions for treating a pulmonary disorder according to the methods described herein. Another more specific embodiment of the present invention provides a medical kit, e.g., comprising (i) a composition described herein and (ii) instructions for treating pain according to the methods described herein. [Example]
[0269] The invention having now been generally described will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to be limiting of the invention.
[0270] Example 1 - Preparation of stromal vascular cells Stromal vascular cell populations for administration to patients were prepared according to the general procedure described below.
[0271] Part I - Obtaining adipose tissue from patients Approximately 30 minutes before the start of the adipose tissue extraction procedure, the patient is anesthetized or administered one of the following drugs: levofloxacin, diazepam, or oxycodone. The area of the patient undergoing adipose tissue extraction is numbed by injecting a 1% (w / w) lidocaine solution (1:100,000) containing epinephrine. Administer no more than 4 mL of the 1% (w / w) lidocaine solution to the patient.
[0272] A tumescent solution was prepared using a 500 mL bag of saline, 25 mL of an aqueous solution containing 1% (w / w) lidocaine, and 0.5 mL of an aqueous solution containing epinephrine (1:10,000). 120 mL of the tumescent solution was administered to the patient using a Tulip 14-gauge 2.1 mm x 15 cm inflator with a 60 mL BD LuerLok syringe. After a 10-minute period, lipoaspirate extraction began. 80 mL to 200 mL of lipoaspirate was extracted from the patient using a Tulip Premium Single-Use Miller SuperLuerlok 2.11 mm OD (1.70 mm ID) x 15 cm inflator with a 60 mL BD LuerLok syringe with a Johnny Lock system. Approximately three to five 60 mL BD syringes were used to obtain the lipoaspirate. The syringes were capped and positioned upright. Steri-Strips were used to close the patient's wound(s).
[0273] Part II - Processing of adipose tissue to obtain stromal vascular cells Adipose tissue obtained from patients in Part I was subjected to the following general procedure to obtain stromal vascular cells, and all materials used in the procedure were sterilized before use. 1) A 250 mL container is filled with up to 150 mL of liposuction tissue obtained from the patient. 2) Place the 250 mL container containing the lipoaspirate into the sonicator. a) Immerse the container in the sonicator bath above the sonicator cup horn. The container is positioned at least 3 mm above the cup horn, but the container is not in contact with the cup horn in the sonicator bath. b) No probe is used to lyse the cells by sonication. Nothing but the sample itself is placed in the sonication bottle, which is closed during the sonication process. This minimizes the risk of contamination with pathogens or cross-contamination with other patient cells. 3) The lipoaspirate tissue is sonicated for a duration of 5 minutes. a) Sonication is performed at 70-90% amplitude, alternating 1 minute pulses with 10 seconds to 1 minute pauses in between, preferably a minimum pause of 10 seconds. b) The sonicator operates at a frequency of 20 kHz. c) The lipoaspirate is kept at a constant temperature of 20°C by circulating water maintained at a constant temperature. Sonication generates heat, but the thermostatic bath dissipates the heat and keeps the sample at 20°C, thereby enhancing stem cell vitality during processing and avoiding thermal denaturation. Maintaining the sonication bottle above, rather than over the cup horn, also reduces heat transfer. 4) Once sonication is complete, pour 25 mL aliquots of the contents of the 250 mL container into 50 mL tubes, add 25 mL of sterile saline to each 50 mL tube, and cap the tubes. 5) Centrifuge the 50 mL tube at 3000 rpm for 5 minutes. 6) Remove the cap from the tube and pour off the adipose tissue (i.e., the supernatant oil layer). 7) Gently mix the remaining contents of the 50 mL tube so that the pellet mixes with the rest of the cells. Add a small amount of saline (e.g., about 5 mL) to the 50 mL tube, then mix the contents to ensure that the buffy coat cells and cell pellet are thoroughly mixed. 8) The contents of the 50 mL tube are filtered to generate a stromal vascular cell population. a) When cryopreserving stromal vascular cells, dimethyl sulfoxide is added to the stromal vascular cells.
[0274] The results of performing the above general procedure on 10 human patients are provided below. [Table 1]
[0275] Total cell count and cell viability were determined using a Luna Flow Stem™ system from Logos Biosystems. When using cells from the adipose stromal vascular fraction (SVF), knowing cell concentration and viability is important. The LUNA-STEM™ system from Logos Biosystems is equipped with dual fluorescence and brightfield optics to distinguish live nucleated cells from dead nucleated cells. The sample was stained with a nucleic acid dye to determine mononuclear cell concentration and viability. Non-nucleated cells were distinguished from debris and counted. High-resolution images, including live cells labeled with green circles and dead cells labeled with red circles, were available for visual confirmation of the data. The harvested cells contained the immunophenotypes CD31, CD34, and CD45, which are protein markers expressed by various cell types involved in tissue formation, immune responses, and other cellular functions. These cells also appeared to co-express another protein marker, CD73, demonstrating the immunophenotypic characteristics of uncultured mesenchymal stem cells (MSCs). MSCs are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells), and adipose tissue.
[0276] Example 2 - Preparation of an injectable pharmaceutical composition containing stromal vascular cells An injectable pharmaceutical composition containing stromal vascular cells for administration to patients was prepared according to the procedure described below.
[0277] An aliquot of stromal vascular cells was combined with sterile saline, which was isotonic.
[0278] Example 3 - Treatment of Chronic Obstructive Pulmonary Disease A 69 year old male human subject was diagnosed with COPD with a pulse oximetry level of 84. The patient underwent stem cell therapy as described below.
[0279] Approximately 120 mL of lipoaspirate tissue was obtained from the patient according to the process for obtaining adipose tissue described in Example 1. The lipoaspirate tissue was processed according to the procedure for obtaining stromal vascular cells described in Example 1 to generate approximately 120 mL of stromal vascular cells. This stromal vascular cell population contained approximately 1.3 billion stromal vascular cells. The viability of all cells in the stromal vascular cell population was at least 95%. Physiological saline was added to the stromal vascular cell population to provide a sufficient amount of stromal vascular cells to complete sessions 1, 2, and 3 (see below) of the protocol for treating COPD.
[0280] Within five hours of obtaining the lipoaspirate from the patient, the stromal vascular cells were introduced into injectable saline, and the resulting mixture was administered to the patient via intravenous injection according to the procedure for Session 1 of the COPD treatment protocol (see below). The patient was evaluated the following day, and it was determined that the patient's pulse oximetry level had improved to 96. The patient then completed Sessions 2 and 3 of the protocol for the treatment of COPD. One week after completing Session 3, the patient was evaluated and it was determined that the patient's respiratory function had dramatically improved compared to that before Session 1. Protocols for the Treatment of COPD a. Session 1 (Day 1): A first injectable pharmaceutical composition prepared by mixing 250 mL of saline with an aliquot of stromal vascular cells ranging from 80 mL to 100 mL is administered intravenously to the patient over a duration of 35 minutes; b. Session 2 (Day 2): A second injectable pharmaceutical composition prepared by mixing 250 mL of saline with an aliquot of stromal vascular cells ranging from 40 mL to 60 mL is administered intravenously to the patient over a duration of 35 minutes; c. Session 3 (Day 3): A second injectable pharmaceutical composition prepared by mixing 250 mL of saline with an aliquot of stromal vascular cells ranging from 40 mL to 60 mL is administered intravenou...
Claims
1. 1. An injectable pharmaceutical composition comprising a population of stromal vascular cells for use in the treatment of a pulmonary or metabolic disorder, or in the treatment or prevention of a coronavirus infection, comprising: (i) For the treatment of a pulmonary disorder, said uses include: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; and d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing from about 300 million to about 2 billion cells for a duration of about 35 minutes; wherein the stromal vascular cell population is obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes; (ii) For the treatment of a metabolic disorder, said use includes: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 14 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; c. On about day 35 after day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; d. On about 65 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and e. On about 95 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or a sonication probe; or (iii) For the treatment or prevention of a coronavirus infection, said use includes: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; and d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing from about 300 million to about 2 billion cells for a duration of about 35 minutes; wherein the stromal vascular cells are obtained from adipose tissue by sonication of aspirated adipose tissue and without the use of enzymes or sonication probes; Injectable pharmaceutical compositions.
2. 13. An injectable pharmaceutical composition for use according to claim 1 for the treatment of lung disorders, said use comprising: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; and d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing from about 300 million to about 2 billion cells for a duration of about 35 minutes; wherein the stromal vascular cells are obtained from adipose tissue by sonication of aspirated adipose tissue and without the use of enzymes or sonication probes; Injectable pharmaceutical compositions.
3. 3. The injectable pharmaceutical composition for use according to claim 1 or 2, wherein the first injectable pharmaceutical composition comprises saline and an aliquot of a stromal vascular cell population containing from about 900 million to about 1.5 billion cells.
4. 4. The injectable pharmaceutical composition for use according to any one of claims 1 to 3, wherein the second injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cell population containing from about 400 million to about 1 billion cells.
5. 5. The injectable pharmaceutical composition for use according to any one of claims 1 to 4, wherein the third injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cell population containing from about 400 million to about 1 billion cells.
6. 6. The injectable pharmaceutical composition for use according to any one of claims 1 to 5, wherein the fourth injectable pharmaceutical composition comprises saline and an aliquot of a stromal vascular cell population containing from about 400 million to about 1 billion cells.
7. 7. The injectable pharmaceutical composition for use according to any one of claims 1 to 6, wherein the first injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline or has a volume of about 330 mL to about 350 mL.
8. 8. The injectable pharmaceutical composition for use according to any one of claims 1 to 7, wherein the second injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline or has a volume of about 290 mL to about 310 mL.
9. 9. The injectable pharmaceutical composition for use according to any one of claims 1 to 8, wherein the third injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline or has a volume of about 290 mL to about 310 mL.
10. 10. The injectable pharmaceutical composition for use according to any one of claims 1 to 9, wherein the fourth injectable pharmaceutical composition contains about 240 mL to about 290 mL of saline or has a volume of about 290 mL to about 310 mL.
11. 11. The injectable pharmaceutical composition for use according to any one of claims 1 to 10, further comprising the step of obtaining adipose tissue from the patient and processing it to provide a population of stromal vascular cells for use in the first injectable pharmaceutical composition prior to intravenously administering the first injectable pharmaceutical composition to the patient on day 1.
12. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the pulmonary disorder is chronic obstructive pulmonary disease.
13. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the pulmonary disorder is asthma.
14. 12. An injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein said pulmonary disorder is bronchitis, optionally chronic bronchitis.
15. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the pulmonary disorder is emphysema.
16. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the pulmonary disorder is acute respiratory distress syndrome.
17. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the lung disorder is an infection with a coronavirus, optionally an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
18. 12. The injectable pharmaceutical composition for use according to any one of claims 1 to 11, wherein the pulmonary disorder is pneumonia or pleural effusion.
19. 19. The injectable pharmaceutical composition for use according to any one of claims 1 to 18, wherein the patient experiences at least a 25% reduction in symptoms from the pulmonary disorder within one week from the first day of the treatment, or at least a 50% reduction in symptoms from the pulmonary disorder within one week from the first day of the treatment.
20. 1. An injectable pharmaceutical composition comprising a population of stromal vascular cells for use in the treatment of a disorder selected from a neurodegenerative disorder, a brain injury, a psychiatric disorder or pain, comprising: (i) for the treatment of a neurodegenerative disorder, said use including: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 30 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and c. On about 60 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cell population is obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes; (ii) for the treatment of brain injury or psychiatric disorders, said uses including: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 30 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and c. On about 60 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cell population is obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes; (iii) For the treatment of pain, said uses include: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 90 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and c. On about 210 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cells are obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or a sonication probe; or (iv) For the treatment of pain, said uses include: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 30 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; c. On about 60 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; d. On about 90 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and e. On about 120 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cells are obtained from adipose tissue by sonication of aspirated adipose tissue and without the use of enzymes or sonication probes; Injectable pharmaceutical compositions.
21. 21. An injectable pharmaceutical composition for use according to claim 20, comprising: (a) the use is for the treatment of a neurodegenerative disorder, and said first injectable pharmaceutical composition comprising saline and an aliquot of a stromal vascular cell population containing from about 200 million to about 800 million cells; the second injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing from about 500 million to about 2.5 billion cells; said first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min; the first injectable pharmaceutical composition has a volume of about 200 mL; said second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min; said second injectable pharmaceutical composition having a volume of about 200 mL to about 450 mL; said use further comprising intravenously administering at least about 100 mL of saline to said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient; said use further comprising intravenously administering to said patient a volume of about 100 mL of saline for a duration of about 25 minutes prior to intravenously administering to said patient said first injectable pharmaceutical composition; said use further comprising, prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, obtaining adipose tissue from said patient and processing it to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; said use further comprising the step of obtaining adipose tissue from said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, or within 3 days prior to day 1, and processing said tissue to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; the neurodegenerative disorder is multiple sclerosis; the neurodegenerative disorder is amyotrophic lateral sclerosis; the neurodegenerative disorder is dementia; the neurodegenerative disorder is Parkinson's disease; The patient experiences at least a 25% reduction in symptoms from the neurodegenerative disorder within three months after the first day of the treatment; or said patient experiences at least a 50% reduction in symptoms from said neurodegenerative disorder within three months after the first day of said treatment; or (b) the use is for the treatment of a disorder selected from the group consisting of brain injury and psychiatric disorders; and said first injectable pharmaceutical composition comprising saline and an aliquot of a stromal vascular cell population containing from about 200 million to about 800 million cells; the second injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing from about 500 million to about 2.5 billion cells; said first injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min; the first injectable pharmaceutical composition has a volume of about 200 mL; said second injectable pharmaceutical composition is administered intravenously at a rate of about 4 to about 6 mL / min; said second injectable pharmaceutical composition having a volume of about 200 mL to about 450 mL; said use further comprising intravenously administering at least about 100 mL of saline to said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient; said use further comprising intravenously administering to said patient a volume of about 100 mL of saline for a duration of about 25 minutes prior to intravenously administering to said patient said first injectable pharmaceutical composition; said use further comprising, prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, obtaining adipose tissue from said patient and processing it to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; said use further comprising the step of obtaining adipose tissue from said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, or within 3 days prior to day 1, and processing said tissue to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; the disorder is brain injury; the disorder is stroke; the disorder is chronic traumatic encephalopathy; the injury is traumatic brain injury; the disorder is a psychiatric disorder; the disorder is post-traumatic stress disorder; the disorder is anxiety; the disorder is post-concussion syndrome; said patient experiences at least a 25% reduction in symptoms from said disorder within three months after day 1 of said treatment; the patient experiences at least a 50% reduction in symptoms from the disorder within three months after the first day of the treatment. Injectable pharmaceutical compositions.
22. 13. An injectable pharmaceutical composition for use according to claim 1 for the treatment of metabolic disorders, said use comprising: a. On day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; b. On about 14 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; c. On about day 35 after day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; d. On about 65 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells for a duration of about 30 minutes; and e. On about 95 days after Day 1: i. administering intravenously to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 200 million to about 1.5 billion cells for a duration of about 45 minutes, followed by ii. administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 200 million to about 4 billion cells over a duration of about 30 minutes; wherein the stromal vascular cell population is obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes; Here, if necessary, said first injectable pharmaceutical composition comprising saline and an aliquot of a stromal vascular cell population containing from about 200 million to about 800 million cells; the second injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing from about 500 million to about 2.5 billion cells; said use comprising intravenously administering a first injectable pharmaceutical composition at a rate of about 4 to about 6 mL / min; the first injectable pharmaceutical composition has a volume of about 200 mL; said use comprising intravenously administering the second injectable pharmaceutical composition at a rate of about 4 to about 6 mL / min; said second injectable pharmaceutical composition having a volume of about 200 mL to about 450 mL; said use further comprising intravenously administering at least about 100 mL of saline to said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient; said use further comprising intravenously administering to said patient a volume of about 100 mL of saline for a duration of about 25 minutes prior to intravenously administering to said patient said first injectable pharmaceutical composition; said use further comprising, prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, obtaining adipose tissue from said patient and processing it to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; said use further comprising the step of obtaining adipose tissue from said patient prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, or within 3 days prior to day 1, and processing said tissue to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition and said second injectable pharmaceutical composition administered intravenously to said patient on day 1; the metabolic disorder is diabetes; the metabolic disorder is type I diabetes, type 2 diabetes, or metabolic syndrome; said patient experiences at least a 25% reduction in symptoms from said disorder within four months after the first day of said treatment; or the patient experiences at least a 50% reduction in symptoms from the disorder within four months after the first day of the treatment. Injectable pharmaceutical compositions.
23. 10. An injectable pharmaceutical composition for use according to claim 1 for the treatment or prevention of coronavirus infection, said use comprising: a. on day 1, intravenously administering to a patient in need thereof a first injectable pharmaceutical composition containing saline and an aliquot of a stromal vascular cell population containing about 700 million to about 3 billion cells over a duration of about 35 minutes; b. on the day following day 1, administering intravenously to a patient in need thereof a second injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; c. 2 days after day 1, intravenously administering to a patient in need thereof a third injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing about 300 million to about 2 billion cells for a duration of about 35 minutes; d. 3 days after day 1, intravenously administering to a patient in need thereof a fourth injectable pharmaceutical composition containing saline and an aliquot of stromal vascular cells containing from about 300 million to about 2 billion cells for a duration of about 35 minutes; wherein the stromal vascular cell population is obtained from adipose tissue by sonication of lipoaspirate tissue and without the use of enzymes or sonication probes; Here, if necessary, said first injectable pharmaceutical composition comprising saline and an aliquot of a stromal vascular cell population containing from about 900 million to about 1.5 billion cells; said second injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cell population containing from about 400 million to about 1 billion cells; said third injectable pharmaceutical composition comprising saline and an aliquot of stromal vascular cells containing from about 400 million to about 1 billion cells; the fourth injectable pharmaceutical composition comprises saline and an aliquot of stromal vascular cells containing from about 400 million to about 1 billion cells; the first injectable pharmaceutical composition comprises about 240 mL to about 290 mL of saline; the first injectable pharmaceutical composition has a volume of about 330 mL to about 350 mL; said second injectable pharmaceutical composition comprising from about 240 mL to about 290 mL of saline; said second injectable pharmaceutical composition having a volume of about 290 mL to about 310 mL; the third injectable pharmaceutical composition comprises about 240 mL to about 290 mL of saline; said third injectable pharmaceutical composition having a volume of about 290 mL to about 310 mL; the fourth injectable pharmaceutical composition comprises about 240 mL to about 290 mL of saline; the fourth injectable pharmaceutical composition has a volume of about 290 mL to about 310 mL; prior to intravenously administering said first injectable pharmaceutical composition to said patient on day 1, further comprising obtaining adipose tissue from said patient and processing it to provide a population of stromal vascular cells for use in said first injectable pharmaceutical composition; the coronavirus infection is an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); The coronavirus infection is an infection with a mutant strain of SARS-CoV-2; the coronavirus infection is an infection with a mutant strain of SARS-CoV-2 having the spike protein of SARS-CoV-2; The coronavirus infection is an infection with SARS-CoV-2 or a variant thereof selected from B.1.617.2, cluster 5, lineage B.1.1.207, lineage B.1.1.7, variant of concern 202102 / 02, lineage B.1.1.317, lineage B.1.1.318, lineage B.1.351, lineage B.1.429, lineage B.1.525, lineage P.1 (also known as lineage B.1.1.28), D614G, E484K, N501Y, S477G / N, and P681H; the patient is suffering from cognitive impairment due to the coronavirus infection; the patient is immunocompromised; said use improving immune function, thereby promoting recovery from coronavirus infection; said use improving immune function reducing the risk of contracting coronavirus infection; said use enhancing the repair of patient tissue damaged by coronavirus infection; The use enhances repair of patient tissue selected from lung tissue, kidney tissue, and pancreatic tissue damaged by coronavirus infection. The use enhances the repair of fibrous or scar tissue resulting from coronavirus infection; or said use treating said coronavirus infection; Injectable pharmaceutical compositions.
24. (i) at least 80% of the cells in the aliquot of stromal vascular cells are viable; (ii) at least 85% of the cells in the aliquot of stromal vascular cells are viable; or (iii) at least 90% of the cells in the aliquot of stromal vascular cells are viable; 24. An injectable pharmaceutical composition for use according to any one of claims 1 to 23, further characterized by:
25. 24. The injectable pharmaceutical composition for use according to any one of claims 1 to 23, wherein at least 95% of the cells in said aliquot of stromal vascular cells are viable, or at least 98% of the cells in said aliquot of stromal vascular cells are viable.
26. 26. The injectable pharmaceutical composition for use according to any one of claims 1 to 25, wherein the stromal vascular cells are autologous stromal vascular cells, optionally derived from adipose tissue obtained from the patient's abdomen.
27. 27. An injectable pharmaceutical composition for use according to any one of claims 1 to 26, wherein the stromal vascular cell population comprises cells with the immunophenotypes CD31, CD34, and CD45, or comprises cells with the immunophenotypes CD31, CD34, CD45, and CD73.
28. 28. An injectable pharmaceutical composition for use according to any one of claims 1 to 27, wherein the stromal vascular cell population comprises mesenchymal stem cells, optionally wherein at least 25% of the cells in the stromal vascular cell population are mesenchymal stem cells, or about 30% to about 40% of the cells in the stromal vascular cell population are mesenchymal stem cells.
